

The genetic architecture of changes in adiposity during adulthood

Samvida S. Venkatesh^{1,2*}, Habib Ganjgahi³, Duncan S. Palmer^{2,4}, Kayesha Coley⁵,
Laura B. L. Wittemans^{2,4}, Christoffer Nellaker^{2,4}, Chris Holmes^{3,6,7},
Cecilia M. Lindgren^{1,2,4,8}, George Nicholson^{3*}

¹Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, UK

²Big Data Institute at the Li Ka Shing Centre for Health Information and Discovery, University of Oxford, UK

³Department of Statistics, University of Oxford, UK

⁴Nuffield Department of Women's and Reproductive Health, Medical Sciences Division, University of Oxford, UK

⁵Department of Population Health Sciences, University of Leicester, UK

⁶Nuffield Department of Medicine, Medical Sciences Division, University of Oxford, UK

⁷The Alan Turing Institute, London, UK

⁸Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA

1 Abstract

2 Obesity is a heritable disease, characterised by excess adiposity that is measured by body mass index
3 (BMI). While over 1,000 genetic loci are associated with BMI, less is known about the genetic contribution
4 to adiposity trajectories over adulthood. We derive adiposity-change phenotypes from 1.5 million primary-
5 care health records in over 177,000 individuals in UK Biobank to study the genetic architecture of weight-
6 change. Using multiple BMI measurements over time increases power to identify genetic factors affecting
7 baseline BMI. In the largest reported genome-wide study of adiposity-change in adulthood, we identify
8 novel associations with BMI-change at six independent loci, including rs429358 (a missense variant in
9 *APOE*). The SNP-based heritability of BMI-change (1.98%) is 9-fold lower than that of BMI, and higher
10 in women than in men. The modest genetic correlation between BMI-change and BMI (45.2%) indicates
11 that genetic studies of longitudinal trajectories could uncover novel biology driving quantitative trait values
12 in adulthood.

13 Introduction

14 Obesity, the accumulation of excess body fat¹ which is associated with increased disease burden^{2,3}, has a
15 strong genetic component⁴. The heritability of body mass index (BMI) is estimated to be 40%-70%⁴⁻⁶, and
16 genome-wide association studies (GWASs) have implicated over 1,000 independent loci associated with a
17 range of obesity traits⁴. The dynamic process of change in weight over time is also thought to have a genetic
18 component^{7,8}. Recent studies reveal the shifting genetic landscape of infant, childhood, and adolescent BMI,
19 which detect age-specific transient effects by performing age-stratified GWASs⁹⁻¹¹. Adult twin studies¹²⁻¹⁴
20 and electronic health record (EHR) based population studies¹⁵ indicate that long-term patterns of change

*Corresponding authors: samvida@well.ox.ac.uk, george.nicholson@stats.ox.ac.uk

21 in adiposity are heritable and have a distinct genetic component to baseline obesity levels. However, less is
22 known about the specific variants and genes that contribute to patterns of adulthood adiposity change. This
23 paucity of GWASs of long-term trajectories of weight change can be partially attributed to the challenges in
24 building and maintaining large-scale genetics cohorts that follow participants over their lifetime¹⁶.

25 Longitudinal data are a key feature of EHRs, whose increased adoption in the clinic and integration into
26 biobanks has powered cost-efficient and scalable genetics research^{17,18}. Despite biases in EHR data, includ-
27 ing sparsity, non-random missingness, data inaccuracies, and informed presence, EHR-based genetics studies
28 reliably replicate results from purpose-built cohorts¹⁹⁻²¹. Recent advances in the extraction of phenotypes
29 from longitudinal EHRs at scale show that, as expected^{22,23}, the mean of repeat quantitative measurements
30 can outperform cross-sectional phenotypes for genetic discovery^{24,25}. Repeat measurements further allow for
31 the estimation of longitudinal metrics of trait change, such as trajectory-based clusters²⁶, linear slope²⁷, and
32 within-individual variability over time²⁸, all of which may provide additional information to uncover the genetic
33 underpinnings of disease.

34 A variety of approaches are available for harnessing the longitudinal component of trajectories in EHR data.
35 Simple models target the gradient of a linear fit over time, such as in a longitudinal linear mixed-effects
36 model framework²⁸⁻³⁰. More complex regression modelling approaches are employed to investigate non-linear
37 changes over time. For example, semiparametric regression models³¹ generate flexible longitudinal patterns
38 from combinations of basis functions, such as B-splines, regularised to induce a suitable degree of temporal
39 smoothness³²⁻³⁵. Subgroups of individuals with similar non-linear trajectories are often identified through
40 clustering approaches, with subgroup membership then tested for association with clinical outcomes or genetic
41 variation³⁶⁻⁴¹. Although it is possible to fit full joint models that incorporate both genetic data and longitudinal
42 trajectories simultaneously²⁸, two-stage approaches wherein summary metrics from models of longitudinal
43 EHRs are taken forward for genetic association analyses are popular for their computational efficiency²⁷.

44 In this study, we leveraged longitudinal primary care EHRs linked to the UK Biobank (UKBB) cohort⁴² to
45 study the genetic architecture of change in adiposity over adulthood. We developed a two-stage analytical
46 pipeline, utilising statistical methods with a history of application in the EHR data context, to derive linear
47 and non-linear trajectories of BMI and weight over time, and to identify clusters of individuals with similar
48 adiposity trajectories. In the second stage, we carried forward the latent phenotypes from these models, which
49 capture both baseline obesity trait levels and change in obesity traits over time, to perform the largest reported
50 genome-wide association analyses for adiposity-change in adulthood. Our results demonstrate the power and
51 added value of EHR-derived longitudinal phenotypes for genetic discovery.

52 Results

53 Longitudinal data help identify novel genetic signals for obesity

54 We obtained BMI and weight records for up to 177,098 individuals of white British ancestry with up to 1.48
 55 million measurements in UKBB longitudinal records from general practitioner (GP) and UKBB assessment
 56 centre measurements (**Table 1** and **Supp. Fig. 3**). For each individual, we then estimated linear change
 57 in BMI or weight over time using a linear mixed-effects model including random intercepts and random
 58 longitudinal gradients (**Figure 1A**) within six *strata*—defined as the six pair-wise combinations of the two
 59 traits (BMI, weight) with the three sex subsets (women, men, combined sexes).




Figure 1: Modelling of longitudinal obesity trait trajectories. (A) Weight trajectories over time, measured as years from first measurement, in a random sample of 12 individuals in the sex-combined strata. Black points display observed weight records, with blue and pink lines representing predicted fits from linear mixed effects models and regularised high-dimensional spline models respectively. **(B)** Trajectories of cluster centroids, plotted as standardised (std.) and covariate-adjusted (adj.) weight over time (years from first measurement), for the four clusters determined via partitioning-around-medoids (PAM) clustering with a customised distance matrix (see Methods) constructed from the high-dimensional B-spline coefficients estimated in (A). **(C)** Weight trajectories over time for a random sample of individuals in the 99th percentile probability of belonging to each cluster, as determined by parametric bootstrap. The lines display predicted fits and ribbons represent 95% confidence intervals around the mean fit.

60 We first investigated whether the individual-level random intercept terms outputted by the longitudinal linear
 61 mixed-effects (LME) model, by sharing information across multiple BMI measurements, provided higher sta-
 62 tistical power for GWAS than one based on a single, cross-sectional BMI measurement per individual. Despite
 63 our GWAS being 4-fold smaller than the largest published analyses⁴³, we identify 14 novel loci and refine
 64 53 previously described signals for obesity traits among the 374 unique fine-mapped lead single nucleotide
 65 polymorphisms (SNPs) ($P < 5 \times 10^{-8}$) across all strata (**Figure 2A** and (**Supp. Table 2**), see Methods

66 for conditional analysis to classify novel, refined, and reported SNPs⁴⁴). The 53 refined SNPs are condition-
67 ally independent of and represent stronger associations ($P < 0.05$) than published SNPs in this population.
68 Together, the refined and novel SNPs explain 0.33% of variance in baseline BMI (in addition to the 2.7%
69 explained by previously published SNPs), and 0.83% of variance in baseline weight (in addition to the 4.7%
70 explained by previously reported SNPs) (**Figure 2B**). We further quantified the power gained from estimat-
71 ing baseline BMI over repeat longitudinal measurements per individual by comparing genome-wide significant
72 (GWS) SNPs from our baseline BMI GWAS to the largest published BMI meta-analysis to date⁴³. We observe
73 an increase in median chi-squared statistics of GWS SNPs from either study of between 13.4% (females) to
74 14.8% (males) in our GWAS over what would be expected from a cross-sectional GWAS of equivalent sample
75 size.

76 Four of the 14 novel SNPs replicate at $P < 3.6 \times 10^{-3}$ (family-wise error rate (FWER) controlled at 5% across
77 14 tests using the Bonferroni method) in UKBB assessment centre measurements of cross-sectional obesity
78 in up to 230,861 individuals not included in the discovery GWAS (**Supp. Table 3**). One such novel variant
79 is rs7962636 ($\beta = 0.023$ standard deviation (SD) increase in expected baseline weight, $P = 3.7 \times 10^{-12}$),
80 whose nearest gene *MED13L* is a transcriptional regulator of white adipocyte differentiation⁴⁵. Twelve of the
81 14 novel SNPs have a significant ($P < 3.6 \times 10^{-3}$) association with an obesity-related trait in published
82 GWASs that include non-UKBB participants (**Supp. Table 3**). These include rs2861761, whose nearest gene
83 *TENM2* is enriched in white adipocytes⁴⁶, rs13059102, whose nearest gene *BCHE* encodes the liver enzyme
84 butyrylcholinesterase that is associated with obesity via its effect on the ghrelin pathway⁴⁷⁻⁴⁹, rs11156978
85 whose nearest gene *CHD8* is associated with impaired glucose tolerance in mouse knockouts⁵⁰, and rs17794645,
86 whose nearest gene is *ERCC4*, deficiency of which is associated with decreased body weight in mice⁵¹.

87 Ascertainment bias in our discovery cohort could arise from the over-representation of heavier participants in
88 EHR data (**Supp. Table 4**)⁵². On average, women with ten or more weight measurements are 8.3 kg (3.7 units
89 of BMI) heavier than their counterparts with 1-3 measurements; for men, this is an 8.2 kg (3.1 units of BMI)
90 difference. However, the BMI intercept metric from our longitudinal data is genetically perfectly correlated
91 with the un-ascertained cross-sectional BMI in Genetic Investigation of ANthropometric Traits (GIANT) 2019⁴³
92 ($r_G = 1$ and $P < 1 \times 10^{-16}$ in all strata), and 96% of the GWS associations ($P < 5 \times 10^{-8}$) identified in
93 our GWAS have either been reported, or are correlated with reported obesity-associated SNPs in the GWAS
94 Catalog⁵³ (**Supp. Table 1**).

95 ***APOE* missense variant rs429358 is associated with weight loss over time, inde-** 96 **pendent of baseline obesity**

97 To identify genetic variants that affect change in adiposity over time, we performed GWASs for patterns
98 of BMI and weight change adjusted for baseline measurements, defined in two ways. First, we created

99 a linear phenotype from subject-specific random gradients, estimated within a linear mixed-effects model
100 framework, adjusted for corresponding random intercepts, and transformed with a rank-based inverse normal
101 transformation (see Methods). To capture non-linear patterns of temporal change, we additionally modelled
102 longitudinal variation in obesity traits using a regularised high-dimensional B-spline basis³¹ (**Figure 1**). Within
103 each of the six strata, we identified four clusters of individuals using *k*-medoids clustering^{54,55}, representing
104 high gain (k1), moderate gain (k2), stable (k3), and loss (k4) trajectories (**Figure 1** and **Supp. Fig. 5**).
105 We then estimated each individual's probability of belonging to a cluster based on their posterior non-linear
106 obesity trait trajectory. We performed GWASs on the logit-transformed posterior probabilities of k1, k1 and
107 k2 (high and moderate gain clusters), and k1, k2, and k3 (all but the loss cluster) membership, adjusted for
108 the baseline obesity trait (see Methods).

109 A common missense variant in *APOE* (rs429358) is associated with decrease in both BMI and weight over
110 time, and lower posterior probabilities of gain-cluster membership in all analysis strata (**Table 2**). Each copy
111 of the minor C allele of rs429358 (minor allele frequency (MAF)=0.16) is associated with 0.060 SD decrease
112 (95% confidence interval (CI)=0.050-0.069, $P = 8.6 \times 10^{-35}$) in expected BMI slope over time and 0.063 SD
113 decrease (0.054-0.072, $P = 6.0 \times 10^{-42}$) in expected weight slope over time (**Figure 3A**). Independent of
114 baseline obesity, carriers of the minor C allele of rs429358 are at lower odds of membership in the high-gain BMI
115 and weight clusters (odds ratio (OR)=0.976, 95% CI=0.97-0.98, $P < 4.9 \times 10^{-19}$), lowering the membership
116 posterior probability from 40% to 39% on average (**Figure 3B**). Although the minor allele of rs429358 is also
117 associated with lower baseline BMI ($\beta = 0.015$ SD lower BMI intercept, 95% CI=0.0054-0.024) and weight
118 ($\beta = 0.011$ SD lower weight intercept, 95% CI=0.0029-0.020), these associations do not reach genome-wide
119 significance in any analysis strata ($P > 0.002$).

120 The association of rs429358 with adiposity-change phenotypes, across all strata, was replicated at $P < 5 \times 10^{-3}$
121 in up to 17,035 individuals in UKBB with multiple measurements of weight and BMI at repeat assessment
122 centre visits who were excluded from the discovery set (**Supp. Table 5**). Based on 301,943 UKBB participants
123 who reported weight change in the last year as "gain", "about the same", or "loss", and who were not included
124 in the discovery GWAS, we found that carriers of each additional copy of the minor C allele of rs429358 are at
125 0.956 (95% CI=0.94-0.97) lower odds of being in a higher ordinal weight-gain category, independent of their
126 BMI (**Figure 3C** and **Supp. Table 6**). We observe consistent effect direction of the rs429358 association
127 with both estimated and self-reported weight loss over time in individuals who self-identify as Asian (maximum
128 N=8,324 individuals), Black (6,796), mixed (2,681), white not in the white-British ancestry subset (47,174),
129 and other (3,994) ethnicities (see Methods for ancestral group definitions, **Supp. Fig. 1** and **Supp. Table**
130 **7**).

131 Finally, we tested for the effect of rs429358 on change in abdominal adiposity in up to 44,154 individuals of
132 white British ancestry in UKBB who were not in the discovery set, with repeated assessment centre measure-
133 ments of waist circumference (WC) and waist-to-hip ratio (WHR). Each copy of the C allele is associated with

134 0.040 SD decrease (95% CI=0.021-0.049, $P = 2.3 \times 10^{-5}$) in expected WC slope over time and 0.031 SD
135 decrease (0.012-0.050, $P = 1.1 \times 10^{-3}$) in expected WHR slope over time, independent of baseline values
136 (**Figure 3D** and **Supp. Table 6**). While the effect direction remains consistent, these associations are no
137 longer significant upon adjustment for BMI (all $P > 0.1$), suggesting that the observed loss in abdominal
138 adiposity over time may represent a reduction in overall adiposity.

139 The *APOE* locus is a highly pleiotropic region that is associated with lipid levels^{56,57}, Alzheimer's dis-
140 ease^{58,59}, and lifespan^{60,61}, among other traits⁶². Excluding the 242 individuals with diagnoses of dementia
141 or Alzheimer's disease in our replication datasets did not alter associations of rs429358 with any of the longi-
142 tudinal obesity traits (**Supp. Fig. 2**), indicating that they are unlikely to be driven solely by weight loss that
143 accompanies dementia. We additionally performed a longitudinal phenome-wide scan to test for the associ-
144 ation of rs429358 with changes in 45 quantitative biomarkers obtained from the UKBB-linked primary care
145 records. Each copy of the C allele is associated with an increase in expected slope change over time of total
146 cholesterol ($\beta = 0.030$ SD increase, $P = 6.4 \times 10^{-12}$), C-reactive protein (CRP) ($\beta = 0.026$, $P = 9.6 \times 10^{-7}$),
147 and high-density lipoprotein (HDL) cholesterol ($\beta = 0.022$, $P = 1.0 \times 10^{-5}$), but a decrease in expected slope
148 change over time of triglycerides ($\beta = -0.027$, $P = 2.7 \times 10^{-7}$), potassium ($\beta = -0.023$, $P = 3.9 \times 10^{-6}$),
149 lymphocytes ($\beta = -0.020$, $P = 4.0 \times 10^{-5}$), and haemoglobin concentration ($\beta = -0.016$, $P = 1.0 \times 10^{-3}$)
150 (FWER controlled at 5% across 45 tests via the Bonferroni method) (**Figure 3E** and **Supp. Table 8**).

151 **Genome-wide architecture of change in adiposity over time is sex-specific and** 152 **distinct from baseline adiposity**

153 We identify six independent genetic loci associated with distinct longitudinal trajectories of obesity traits by
154 performing GWAS on individuals' posterior probabilities of membership in the high gain cluster (k1), high and
155 moderate gain clusters (k1 and k2), or no loss (clusters k1, k2, and k3), adjusted for baseline obesity trait
156 (**Table 2**). This included the *APOE* locus and five signals in intergenic regions. rs9467663 (OR=1.011 for
157 membership in the high-gain weight cluster, $P = 1.6 \times 10^{-9}$) and chr6:26076446 (OR=1.012 for membership in
158 the high-gain BMI cluster, $P = 2.1 \times 10^{-9}$), are reported associations with haematological traits⁶³. We identify
159 two SNPs, rs11778922 and rs61955499, with female-specific effects on BMI change. rs11778922 (OR=0.984
160 for membership in the high-gain BMI cluster, $P = 1.3 \times 10^{-8}$, sex-heterogeneity $P_{sex-het} = 5.8 \times 10^{-4}$,
161 see Methods) has previously been nominally associated with BMI in females⁴³, and rs61955499 (OR=1.070
162 for membership in the BMI loss cluster, $P = 3.4 \times 10^{-8}$, $P_{sex-het} = 4.7 \times 10^{-5}$), has previously been
163 nominally associated with low-density lipoprotein (LDL) cholesterol levels⁶⁴. Finally, rs12953815 is associated
164 with male-specific weight change (OR=1.012 for membership in the weight loss cluster, $P = 1.7 \times 10^{-8}$,
165 $P_{sexhet} = 2.0 \times 10^{-5}$) and has been previously nominally associated with lung function⁶⁵.

166 The smaller number of independent GWS associations with adiposity change: 6, compared to 374 unique

167 lead SNPs associated with baseline obesity traits, which is expected given the 7- to 9-fold lower heritability of
168 adiposity change. The heritability explained by genotyped SNPs (h_G^2)⁶⁶ of the posterior probability of belonging
169 to an adiposity-gain cluster is between 1.38% in men to 2.82% in women, while the h_G^2 of baseline obesity traits
170 varies between 21.6% to 29.0% across strata (**Figure 4**). Furthermore, we observe that the heritability of BMI
171 and weight trajectories are higher in women than in men (2.89% vs 1.05% for BMI slopes, $P_{sexhet} = 0.012$;
172 and 3.42% vs 1.69% for weight slopes, $P_{sexhet} = 9.9 \times 10^{-3}$). We do not observe a corresponding difference
173 in the h_G^2 of baseline BMI or weight between the sexes ($P_{sexhet} > 0.1$). Finally, baseline and change in obesity
174 traits are genetically correlated, with r_G ranging from 0.35 (95% CI=0.24-0.45) for weight in women to 0.91
175 (0.59-1.23) for BMI in men (**Figure 4**). While the genetic correlation between baseline adiposity and adiposity
176 change appears to be higher in men as compared to women, these estimates have wide confidence intervals
177 (overlapping 1) and $P_{sexhet} > 0.05$ for both BMI and weight.

178 Throughout this study, we evaluate both BMI and weight as obesity traits, and expect these to track closely
179 in adults as height does not change significantly over time. In the 161,891 individuals in our discovery strata
180 with multiple measurements of both BMI and weight, there is a strong correlation between the slopes for
181 weight and BMI change ($r^2 = 0.88$) and between the posterior probabilities of membership in the BMI-gain
182 and weight-gain clusters ($r^2 = 0.73$) (**Supp. Table 9**, all $P < 1 \times 10^{-16}$). Moreover, the genetic correlation
183 between change in BMI and weight is nearly perfect (r_G for slope terms=0.98, r_G for posterior probability
184 of membership in gain cluster=0.95, all $P < 1 \times 10^{-16}$), indicating that the genetic architecture highlighted
185 here is robust to the metric of adiposity used to define trajectories.

186 Discussion

187 In this large-scale EHR- and genetics-based study of longitudinal trajectories of obesity traits, we demonstrate
188 that modelling multiple observations across time increases power to identify genome-wide signals for baseline
189 BMI and weight and enables the discovery of genetic variants associated with changes in adiposity, which are
190 less heritable than and only partially shared with baseline adiposity. Modelling 1.5 million observations of BMI
191 and weight from >177,000 individuals across time enabled us to identify 14 novel, biologically plausible, genetic
192 signals associated with obesity traits. The discovery of these novel loci highlights that repeat measurements
193 can contribute to narrowing the "missing heritability" gap. Leveraging the bespoke longitudinal adiposity
194 phenotypes developed here, we find six genetic loci associated with changes in BMI and weight over time.
195 While previous studies have investigated the associations of cross-sectional BMI SNPs or obesity polygenic
196 scores with adiposity trajectories^{15,68}, to the best of our knowledge, this study reports the first genome-wide
197 scan of variants associated with obesity trait trajectories over adulthood.

198 Accounting for the influence of genetic variation on adiposity change may provide opportunities to personalise
199 obesity prevention and treatment^{69,70}. While several studies have investigated the association between BMI-

200 related genetic variants and weight loss guided by medical⁷¹, surgical^{72,73}, dietary⁷⁴, or behavioural^{71,75–77}
201 interventions, results are inconsistent across studies, intervention types, and genes assessed. Given our evidence
202 that the genetic basis of adiposity change is distinct from baseline levels, we hypothesise that genetic variants
203 associated with longitudinal weight trajectories may be better predictors of long-term weight change following
204 treatment or lifestyle interventions than variants associated with baseline BMI. Moreover, incorporating infor-
205 mation on the genetic signals associated with adiposity trajectories will complement current genetics-based
206 strategies to identify genes for pharmaceutical targets⁷⁸ for obesity treatment.

207 Leveraging EHR to derive longitudinal metrics for genetic discovery may be affected by various biases described
208 earlier⁷⁹. However, the robustness of our results suggests that our discovery dataset may have mitigated
209 against these biases in three ways: (1) While EHR data over-represent sick patients and individuals with
210 higher BMI, UKBB participants are, on average, healthier and have lower BMIs than the population of the
211 United Kingdom (UK)⁸⁰. Therefore our UKBB-linked EHR discovery cohort is more overweight than a random
212 sampling of UKBB, but in contrast UKBB itself is ascertained towards lower-BMI individuals than a random
213 sampling of the UK. (2) Appending the more accurate UKBB assessment centre measurements to the EHR
214 data improves overall data quality. (3) Stringent quality control at both the population and individual level
215 reduces the signal to noise ratio by filtering out a subset of inaccurate data entries. Linking EHRs with biobank
216 data may therefore provide a robust framework for genetic discovery.

217 The two-stage nature of our approach to associate genetic variants with longitudinal trajectories of obesity traits
218 is highly advantageous because of its computational efficiency and convenience. In particular, our method is
219 *composable*, as the longitudinal analysis of raw data can first be performed separately using a choice of popular,
220 efficient implementations of models; the first-stage outputs can then be taken forward to a GWAS performed
221 in its own bespoke, highly optimised software. The two-stage method approximates the fitting of a full
222 joint model incorporating raw measurement data and genome-wide SNP data. While a full joint model would
223 propagate posterior uncertainty from the longitudinal sub-model through to the GWAS, the approximation here
224 takes forward a single point estimate, i.e. a best linear unbiased predictor (BLUP) or posterior probability of
225 cluster membership, to GWAS. However, in EHR datasets, the number of measurements, and hence estimation
226 precision, can vary across individuals. Hence, the propagation of uncertainty between model components, in
227 a similar vein to Markov melding⁸¹, has the potential to further increase power for genetic discovery. An
228 interesting area for future research will be to allow for the principled propagation of posterior uncertainty in
229 inputted traits through to the highly optimised, multi-locus, mixed-model GWAS methods to perform genetic
230 association in the presence of relatedness and population stratification⁸².

231 It is also important that the choice of trajectory metric utilised in genetic analysis is phenotype-aware. While
232 the variance within an individual's trait value over time may capture meaningful biology for biomarkers such as
233 blood pressure or triglycerides, whose fluctuations are associated with disease development and progress^{83,84},
234 weight is a more stable trait which shows a steady pattern of change over many years^{85,86}. Our adiposity-

235 change metrics, derived from regression models incorporating linear and non-linear temporal trends, are better
236 suited to identify the genetic component of BMI and weight trajectories, and are robust to the manner in which
237 this is defined. For example, many of the lead SNPs from our obesity-change GWASs are also associated with
238 self-reported weight change, despite self-report being an imprecise metric⁸⁷.

239 In particular, rs429358 (missense variant in *APOE*) is robustly associated with loss in BMI and weight, inde-
240 pendent of baseline obesity, across men and women, in individuals of various ancestral groups. *APOE* codes
241 for apolipoprotein E, which is a core component of plasma lipoproteins that is essential for cholesterol trans-
242 port and homeostasis in several tissues across the body, including the central nervous system, muscle, heart,
243 liver, and adipose tissue^{88,89}. The precise pathway by which this variant affects weight change is difficult
244 to pinpoint, as *APOE* is a highly pleiotropic locus associated with hundreds of biomarkers and diseases⁶².
245 Here too, we find an association between rs429358 and changes in 11 biomarkers over time. Obesity is cross-
246 sectionally associated with several of these, including positive correlations with levels of triglycerides and total
247 cholesterol^{90,91}, markers of chronic inflammation⁹², and haematological traits⁹³, and negatively correlated
248 with levels of HDL cholesterol^{90,91} and potassium⁹⁴; however, the longitudinal and causal nature of these
249 associations remain to be established. As rs429358 is also the strongest genetic risk factor for Alzheimer's
250 disease^{58,59}, which is preceded by weight loss⁹⁵, we ensured that our findings were robust to the exclusion of
251 individuals with dementia. We hypothesise that the *APOE* effect on weight loss may act through cholesterol-
252 and lipid-metabolism pathways that partly determine response to dietary and environmental factors, as seen in
253 mouse models^{96,97}. Indeed, it has recently been suggested that *APOE*-mediated cholesterol dysregulation in
254 the brain may influence the onset and severity of Alzheimer's disease⁹⁸, suggesting that ageing-associated sys-
255 temic aberrations in cholesterol homeostasis could have far-ranging consequences from weight loss to cognitive
256 decline.

257 Patterns of weight change in mid-to-late adulthood have been observed to be sex-specific, particularly as
258 women undergo significant changes in weight and body fat distribution around menopause⁹⁹. Here, we find
259 that the heritability of changes in obesity traits is significantly higher in women than in men, supporting a
260 previous finding that obesity polygenic scores are more strongly associated with weight-change trajectories in
261 women than in men⁶⁸. This is in contrast to baseline obesity, which is equally heritable in men and women,
262 both in our study and as previously reported⁴³. The lower genetic correlation between baseline obesity and
263 obesity-change in women as compared to men, while not statistically significant, may nevertheless indicate sex-
264 differential genome-wide contributions to these phenotypes. We hypothesise that sex hormones could explain
265 some of this sex-specificity, particularly through their role in altering overall obesity and fat distribution around
266 menopause^{100,101}. We were under-powered to study the genome-wide architecture of change in adult WC
267 and WHR (ten-fold fewer observations than BMI and weight), whose cross-sectional levels are genetically sex-
268 specific with higher heritability in women⁴³, so more work is needed to disentangle the genetic contribution to
269 changes in adult body fat distribution over time.

270 While the EHR-linked UKBB cohort has driven genetic discovery for a vast array of human traits in popula-
271 tions of European ancestry¹⁰², sample sizes remain under-powered to detect genome-wide associations in other
272 ancestral groups. We were thus limited to replicating European-ancestry associations in other populations,
273 without the ability to discover ancestry-specific variants associated with adult adiposity trajectories. Further-
274 more, despite the inclusion of >200,000 individuals in the first release of the UKBB EHR data, sample sizes
275 remain low to analyse the genetics of longitudinal trajectory metrics, which have lower heritability than the
276 averaged trait value^{15, 103} (~7-9x lower in our study) and are thus more challenging to characterise genetically
277 without corresponding increases in sample size. Another limitation of our study was the exclusion of time-
278 varying covariates, such as medication use, smoking status, and other dietary and environmental covariates
279 from models of adiposity change. It is challenging to extract time-dependent values of these variables from
280 EHRs and difficult to ascertain the direction of causality by which these covariates may be associated with
281 weight change. For example, the use of statins to lower blood pressure may be connected to weight gain,
282 mediated indirectly by change in appetite¹⁰⁴, but high blood pressure may itself be a consequence of weight
283 gain¹⁰⁵. Inappropriate adjustments along this causal pathway may lead to unexpected collider biases¹⁰⁶. In
284 general, despite their longitudinal nature, it is challenging to assign causality to the associations between
285 weight change and covariates or disease diagnoses from EHR observations alone, as there is no prospective
286 study design to follow¹⁰⁷. Advances in emulating randomised control trials from longitudinal EHR are begin-
287 ning to overcome these challenges^{108, 109}, and in the future, it will be critical to incorporate information on
288 genetic risk into these simulated studies.

289 To the best of our knowledge, this is the largest study to date that characterises the genome-wide architecture
290 of adult adiposity trajectories, and the first to identify specific variants that alter BMI and weight in mid- to
291 late-adulthood. We add evidence to support the growing utility of EHRs in genetics research, and particularly
292 highlight opportunities for incorporating longitudinal information to boost power and identify novel associa-
293 tions. In particular, the *APOE*-associated weight loss identified here contributes to a growing body of evidence
294 on the ageing-associated effects of cholesterol dysregulation. Heterogeneity between men and women in the
295 genome-wide architecture of obesity-change and genetic correlation with baseline obesity highlights the impor-
296 tance of distinguishing between the genetic contributions to mean and lifetime trajectories of phenotypes in
297 sex-specific analyses. In the future, the growing integration of EHR with genetic data in large biobanks will al-
298 low us to assess the time-varying associations of rare variants with outsize effects on quantitative traits, as well
299 as to establish genetic and phenotypic relationships among the trajectories of multiple correlated biomarkers
300 across adulthood.

301 Methods

302 Identification and quality control of longitudinal obesity records

303 **UK Biobank.** This study was conducted using the UKBB resource, which is a prospective UK-based cohort
304 study with approximately 500,000 participants aged 40–69 years at recruitment, on whom a range of medical,
305 environmental, and genetic information has been collected⁴². Here, we included 409,595 individuals in the
306 white British ancestry subset identified by Bycroft *et al.*¹¹⁰ who passed genotype quality control (QC) (see
307 below).

308 **Repeat obesity trait measurements.** Obesity-associated traits including BMI and weight were recorded
309 at initial baseline assessment (between 2006-2010), as well as at repeat assessments of 20,345 participants
310 (between 2012-13), and at imaging assessments of 52,596 participants (in 2014 and later). We curated a
311 longitudinal research resource by integrating these repeat UKBB assessment centre measurements with the
312 interim release of primary care records provided by GPs for approximately 45% of the UKBB cohort (~230,000
313 participants, randomly selected)¹¹¹ (**Supp. Fig. 3**). Each individual with at least one BMI record (coded as
314 Clinical Practice Research Datalink (CPRD) code 22K..) or weight record (coded as CPRD code 22A..) in
315 the GP data had their respective UKBB assessment centre measurements appended. Following phenotype and
316 genotype QC, this resulted in 162,666 participants of white British ancestry with multiple BMI measurements
317 and 177,472 participants with multiple weight measurements (**Supp. Fig. 3**).

318 **Quality control.** We performed both population-level and individual-level longitudinal QC. Participants with
319 codes for history of bariatric surgery (**Supp. Table 10**, as identified by Kuan *et al.*¹¹²) were excluded entirely,
320 while BMI and weight observations up to the date of surgery were retained for individuals where this could
321 be determined. Only those measures recorded in adulthood (ages 20 - 80 years) were retained. We excluded
322 implausible observations, defined as more extreme than +/- 10% of the UKBB assessment centre minimum
323 and maximum values respectively (BMI < 10.9 kg/m² or > 82.1 kg/m² and weight < 27 kg or > 217 kg).
324 We further removed any extreme values > 5 SDs away from the population mean to exclude possible technical
325 errors. At the individual level we excluded multiple observations on the same day, which are likely to be
326 recording errors, by only retaining the observation closest to the individual's median value of the trait across
327 all time-points. Finally, we excluded any extreme measurements on the individual level. For individual i with
328 J_i data points represented as (measurement, age) pairs $(y_{i,j}, t_{i,j})$ for $j = 1, \dots, J_i$ ordered chronologically,
329 i.e. $t_{i,1} < \dots < t_{i,J_i}$, a "jump" $P_{i,j}$ for $j = 1, \dots, J_i - 1$ was defined as:

$$P_{i,j} = \log_2 \frac{|y_{i,j+1} - y_{i,j}|/y_{i,j}}{t_{i,j+1} - t_{i,j}}$$

330 We removed data points associated with extreme jumps (> 3 SDs away from the population mean jump, to
331 exclude possible technical errors) by excluding the observation farther from the individual's median value of
332 the trait across all time-points.

333 **BMI and weight validation data.** Participants with BMI and weight observations in UKBB assessment
334 centre measurements who were not included in the interim release of the GP data were held out of discovery
335 analyses (**Supp. Fig. 3**). This resulted in 245,447 individuals with at least one BMI observation and 230,861
336 individuals with at least one weight observation for replication of cross-sectional results. For the replication of
337 longitudinal results, a subset of individuals was used comprising 17,006 individuals with multiple observations
338 of BMI, and 17,035 individuals with multiple observations of weight, from repeat assessment centre visits.

339 **Self-reported weight change data.** At each UKBB assessment centre visit, participants were asked the
340 question: "Compared with one year ago, has your weight changed?", reported as "No - weigh about the
341 same", "Yes - gained weight", "Yes - lost weight", "Do not know", or "Prefer not to answer". We coded the
342 1-yr self-reported weight change response at the first assessment centre visit as an ordinal categorical variable
343 with three levels: "loss", "no change", and "gain", excluding individuals who did not respond or responded
344 with "Do not know" or "Prefer not to answer". We retained 301,943 individuals of white British ancestry that
345 were not included in any of the discovery analyses.

346 **Abdominal adiposity data.** Similar to the BMI and weight validation datasets, we retained the 44,154
347 participants with multiple WC and hip circumference (HC) records across repeat assessment centre visits who
348 were not included in the interim release of the GP data, and hence held out of discovery analyses. WHR
349 was calculated at each visit by taking the ratio of WC to HC. We further calculated WC adjusted for BMI
350 (WCadjBMI) and WHR adjusted for BMI (WHRadjBMI) values at each visit for which WC, HC, and BMI
351 were recorded simultaneously by taking the residual of WC and WHR in linear regression models with BMI as
352 the sole predictor.

353 **Models to define baseline adiposity and adiposity change traits**

354 Individual i has J_i data points represented as (measurement, age) pairs $(y_{i,j}, t_{i,j})$ for $j = 1, \dots, J_i$ ordered
355 chronologically, i.e. $t_{i,1} < \dots < t_{i,J_i}$. The following models are all fitted separately in three strata: female-
356 specific, male-specific, and sex-combined.

357 **Intercept and slope traits for GWAS.** We implement a two-stage algorithm to estimate and preprocess
358 local intercept and slopes of obesity traits to be taken forward to GWAS in both discovery and validation
359 datasets.

360 1. Fit random-slope, random-intercept mixed model with the maximum likelihood estimation procedure in
 361 the `lme4`¹¹³ package in R¹¹⁴. We target two quantities: the baseline value of each individual's clinical
 362 trait (the $\beta_0 + u_{i,0}$ below); and the the linearly approximated rate of change in the trait during each
 363 individual's measurement window (the $\beta_1 + u_{i,1}$ below):

$$y_{i,j} = x_i^T \gamma + (\beta_0 + u_{i,0}) + (\beta_1 + u_{i,1}) \cdot (t_{i,j} - t_{i,1}) + \varepsilon_{i,j} \quad (1)$$

$$u_{i,k} \sim \text{N}(0, \sigma_{u,k}^2), \quad k = 1, 2$$

$$\varepsilon_{i,j} \sim \text{N}(0, \sigma_\varepsilon^2),$$

364 where individual-specific covariates x_i comprise: baseline age, (baseline age)², data provider, year of
 365 birth, and sex. Variance parameters $\sigma_{u,k}^2$ and σ_ε^2 are estimated. Fitting model (1) outputs fixed effect
 366 model estimates $\hat{\gamma}$, $\hat{\beta}_0$, $\hat{\beta}_1$ and BLUPs of the random effects $\hat{u}_{i,0}$ and $\hat{u}_{i,1}$.

367 2. Linearly adjust and transform the outputted BLUPs. We fit and subtract the linear predictor in each of
 368 the linear models:

$$\hat{u}_{i,0} = x_{0,i}^T \gamma_0 + \varepsilon_{0,i} \quad (2)$$

$$\hat{u}_{i,1} = x_{1,i}^T \gamma_1 + \varepsilon_{1,i} \quad (3)$$

369 where the intercept-adjusting covariates $x_{0,i}$ in (2) comprise: baseline age, (baseline age)², sex, year of
 370 birth, assessment centre, number of follow-ups, and total length of follow-up (in years). Slope-adjusting
 371 covariates $x_{1,i}$ in (3) comprise the same as $x_{0,i}$ but additionally include the intercept BLUP $\hat{u}_{i,0}$. We
 372 finally apply a deterministic rank-based inverse normal transformation¹¹⁵ to the residuals from fitting
 373 models (2) and (3). For example, the intercept trait for individual i taken forward to GWAS is

$$\tilde{u}_{i,1} = \Phi^{-1} \left(\frac{r(\hat{u}_{i,1} - x_{0,i}^T \hat{\gamma}_0) - c}{N - 2c + 1} \right) \quad (4)$$

374 where $r(\hat{u}_{i,1} - x_{0,i}^T \hat{\gamma}_0)$ is the rank of the i th residual among all N residuals, the offset c is 0.5, and $\Phi(\cdot)$
 375 is the cumulative distribution function (CDF) of the standard Gaussian distribution.

376 **Modelling nonlinear trajectories with regularised splines.** We model non-linear changes in obesity traits
 377 using a regularised B-spline basis of degree 3 (i.e., a cubic spline model) with $n_{df} = 100$ degrees of freedom,
 378 incorporating $n_{df} - 4$ (i.e., $n_{df} - 3$ [degree] - 1 [intercept]) knots that are spaced evenly across each individual's
 379 first $T = 7500$ post-baseline days ≈ 20.5 years. It is common practice in semi-parametric regression to use
 380 *regularised* splines with a relatively *large* number of knots, thereby allowing functional expressiveness without
 381 overfitting^{31,116}. Conditional on the spline coefficients, \mathbf{b}_i , the likelihood for measurements \mathbf{y}_i (individual i 's

382 J_i -vector of measurements taken at days $t_{i,1}, \dots, t_{i,J_i}$ is

$$p(\mathbf{y}_i | \mathbf{b}_i, \sigma^2) = \text{MVN}(\mathbf{y}_i | \mathbf{Z}_i \mathbf{X}_B \mathbf{b}_i, \mathbf{I} \sigma^2) \quad (5)$$

383 where: the n_{df} -vector \mathbf{b}_i contains the i th individual's spline basis coefficients; \mathbf{X}_B is the $(T+1) \times n_{\text{df}}$ matrix
384 of spline basis functions evaluated at days $0, \dots, T$ post-baseline; and \mathbf{Z}_i is a $J_i \times (T+1)$ matrix whose j th
385 row extracts day $t_{i,j} - t_{i,1}$ post-baseline, i.e.,

$$[\mathbf{Z}_i]_{j,k} = \begin{cases} 1 & \text{if } k = t_{i,j} - t_{i,1} + 1 \\ 0 & \text{otherwise.} \end{cases}$$

386 We specify an order-1 autoregressive ($AR(1)$) model as a smoothing prior on spline coefficients, \mathbf{b}_i , which vary
387 smoothly around an individual-specific mean value, μ_i . On μ_i we specify a non-informative prior: $N(\mu_i | 0, \sigma_\mu^2)$
388 with large SD σ_μ . The resulting μ_i -marginalised prior for \mathbf{b}_i is

$$p(\mathbf{b}_i) = \text{MVN}(\mathbf{b}_i | \mathbf{0}, \boldsymbol{\Sigma}_B) \quad (6)$$

$$\boldsymbol{\Sigma}_B := \boldsymbol{\Sigma}_{AR(1)} + \sigma_\mu^2 \mathbf{1}$$

$$[\boldsymbol{\Sigma}_{AR(1)}]_{k,k'} := \sigma_{AR(1)}^2 \phi^{|k-k'|} ,$$

389 where: $\boldsymbol{\Sigma}_{AR(1)}$ is the $n_{\text{df}} \times n_{\text{df}}$ autocovariance matrix implied by an $AR(1)$ model with lag-1 autocorrelation
390 $\phi \in [0, 1)$ and scale parameter $\sigma_{AR(1)}^2 > 0$; and $\mathbf{1}$ is an $n_{\text{df}} \times n_{\text{df}}$ matrix of ones.

391 The prior at (6) and likelihood at (5) are a specific case of the Bayes linear model¹¹⁷, for which the posterior
392 is available in closed form:

$$p(\mathbf{b}_i | \mathbf{y}_i, \boldsymbol{\Sigma}_B, \sigma^2) = \text{MVN}(\mathbf{b}_i | \mathbf{m}_i, \sigma^2 \mathbf{V}_i) \quad (7)$$

$$\mathbf{V}_i := \left(\mathbf{X}_B^T \mathbf{Z}_i^T \mathbf{Z}_i \mathbf{X}_B + \boldsymbol{\Sigma}_B^{-1} \right)^{-1}$$

$$\mathbf{m}_i := \mathbf{V}_i \mathbf{X}_B^T \mathbf{Z}_i^T \mathbf{y}_i .$$

393 The posterior at (7) can be evaluated separately and in parallel across individuals because the $(\mathbf{y}_i, \mathbf{b}_i)$ are
394 conditionally independent across individuals i given the hyperparameters $\sigma_{AR(1)}^2$, ϕ , σ_μ and σ^2 . Values of
395 hyperparameters in the smoothing prior are chosen subjectively, via visualisation of randomly selected samples
396 of individual data trajectories, to reflect empirical levels of smoothness: $\sigma_{AR(1)}^2 := 2.5$, $\phi := 0.99$, $\sigma_\mu := 100$
397 (**Supp. Fig. 4**). We additionally compared cluster allocations for 5,000 randomly selected individuals across
398 the following settings of hyperparameters: $(\sigma_{AR(1)}^2 := 0.5, \phi := 0.9, \sigma_\mu := 10)$, $(\sigma_{AR(1)}^2 := 2.5, \phi := 0.99,$
399 $\sigma_\mu := 100)$, and $(\sigma_{AR(1)}^2 := 10, \phi := 0.999, \sigma_\mu := 500)$ (**Supp. Fig. 8**).

400 For each trait separately, we set σ^2 to the median of its individual-specific maximum likelihood estimates

401 (MLEs), i.e., $\sigma^2 := \text{median} \left\{ \frac{1}{J_i} \|\mathbf{y}_i - \mathbf{Z}_i \mathbf{X}_B \mathbf{m}_i\|_2^2 : i = 1, \dots, n \right\}$ where each MLE is calculated from (5)
402 after substituting for \mathbf{b}_i its maximum a posteriori estimate, \mathbf{m}_i from (7) (**Supp. Table 12**).

403 The measurements \mathbf{y}_i inputted into the likelihood for the regularised spline model at (5) are pre-processed by
404 taking the standardised residual from the linear model with the following covariates: baseline age, (baseline age)²,
405 data provider, year of birth, and sex, i.e. from the model $\mathbf{y}_{i,j} = x_i^T \boldsymbol{\gamma} + \varepsilon_{i,j}$ fitted across all $i = 1, \dots, N$
406 individuals and $j = 1, \dots, J_i$ time points. Standardisation of residuals then proceeds by subtracting the mean
407 and dividing by the SD of residuals across all individuals and time points.

408 We focus on individual i 's posterior change from baseline, i.e. on

$$\begin{aligned} \tilde{\mathbf{b}}_i &:= (0, u_{i,2} - u_{i,1}, u_{i,3} - u_{i,1}, \dots)^T \\ &\equiv \mathbf{D}\mathbf{b} \end{aligned}$$

409 where the j th row of \mathbf{D} is $(\mathbf{e}_j - \mathbf{e}_1)^T$ and \mathbf{e}_k is the k th basis vector, i.e. a column n_{df} -vector with zeroes
410 everywhere except the k th entry, which is one. To calculate the posterior for $\tilde{\mathbf{b}}_i$ we linearly transform the
411 posterior at (7) so that

$$p(\tilde{\mathbf{b}}_i | \mathbf{y}_i, \boldsymbol{\Sigma}_B, \sigma^2) = \text{MVN}(\tilde{\mathbf{b}}_i | \mathbf{D}\mathbf{m}_i, \sigma^2 \mathbf{D}\mathbf{V}_i \mathbf{D}^T) \quad (8)$$

412 with \mathbf{m}_i and \mathbf{V}_i defined at at (7).

413 **Soft clustering of individuals by non-linear adiposity trajectory patterns.** See **Supp. Fig. 5** for an
414 overview of the clustering protocol.

415 Any two individuals typically have quite distinct measurement profiles, with different numbers of measurements
416 taken at ages which may be quite disparate. Therefore the precision with which we can estimate any particular
417 spline coefficient varies across individuals. To incorporate this heteroscedasticity into our clustering framework,
418 we define the following scaled Euclidean distance between each pair of individuals (i, i') in the space of baselined
419 spline basis coefficients:

$$d(i, i') = \sqrt{\sum_{k=1}^{n_{df}} \frac{([\mathbf{D}\mathbf{m}_i]_k - [\mathbf{D}\mathbf{m}_{i'}]_k)^2}{([\mathbf{D}\mathbf{V}_i \mathbf{D}^T]_{k,k} + [\mathbf{D}\mathbf{V}_{i'} \mathbf{D}^T]_{k,k})\sigma^2}} \quad (9)$$

420 where \mathbf{m}_i and $\sigma^2 \mathbf{V}_i$ are the posterior mean and covariance of individual i 's spine coefficients \mathbf{b}_i taken from
421 (7). For each spline coefficient k in (9), the squared difference between individuals' i and i' mean coefficients
422 is standardised by the sum of the corresponding variances.

423 We perform k -medoids clustering using the the Partitioning Around Medoids (PAM) algorithm^{54,55} as im-
424 plemented in the `pam` function in the `cluster` package¹¹⁸ in \mathbb{R}^{114} . We train cluster centroids on a randomly

425 selected subset of 80% of individuals in each analysis strata. We filter individuals in the training set to retain
426 only those with at least $L = 2$ observations. For a fixed number of clusters, $K = 4$, we initialize cluster
427 membership according to bins $\mathcal{B}_{1:K}$ demarcated by the $0, \frac{1}{K}, \frac{2}{K}, \dots, 1$ empirical quantiles of the estimated
428 fold change in obesity trait between baseline and year $M = 2$:

$$\begin{aligned} \mathcal{B}_k &:= \left[\hat{F}^{-1} \left(\frac{k-1}{K} \right), \hat{F}^{-1} \left(\frac{k}{K} \right) \right] \quad k = 1, \dots, K \\ \hat{F}(\cdot) &:= \text{empirical CDF of } \left\{ \frac{[\mathbf{X}_B \mathbf{Dm}_i]_{M+1}}{[\mathbf{X}_B \mathbf{Dm}_i]_1} : i = 1, \dots, N \right\} \\ \text{individual } i \text{ in bin } k &\iff \frac{[\mathbf{X}_B \mathbf{Dm}_i]_{M+1}}{[\mathbf{X}_B \mathbf{Dm}_i]_1} \in \mathcal{B}_k . \end{aligned} \quad (10)$$

429 To ensure robustness, we run the clustering algorithm $S = 10$ times, each on a random sub-sample of size
430 5,000 (without replacement). For each clustering output $s = 1, \dots, S$, we calculate the point-wise mean of
431 each clusters' constituent individuals:

$$\mathbf{c}_{k,s} := \frac{1}{|\mathcal{C}_k^{(s)}|} \sum_{i \in \mathcal{C}_k^{(s)}} \mathbf{Dm}_i \quad (11)$$

432 For each clustering s , we observe all trajectories $\mathbf{c}_{s,1:K}$ to be monotonic and non-overlapping (**Supp. Fig.**
433 **6**). We can therefore define ordered cluster means $\mathbf{c}_{(k),s}$,

$$k < k' \iff [\mathbf{c}_{(k),s}]_j > [\mathbf{c}_{(k'),s}]_j \quad \forall j = 1, \dots, n_{df} ,$$

434 and average the k th ordered mean across S clusterings, where the highest-weight cluster mean is given by $\mathbf{c}_{(1)}$
435 and the lowest by $\mathbf{c}_{(K)}$:

$$\mathbf{c}_{(k)} := \frac{1}{S} \sum_{s=1}^S \mathbf{c}_{(k),s} ,$$

436 with corresponding point-wise standard errors (SEs). We investigate the sensitivity of the resulting clusters to
437 number of clusters K , filter parameter L (minimum number of measurements), and the cluster initialisation
438 parameter M appearing in (10) via silhouette values¹¹⁹, which evaluate the similarity between cluster members
439 (cohesion) vs others (separation) (**Supp. Fig. 6**). We test values of K from $2, \dots, 8$, filtering parameter
440 $L \in (2, 5, 10)$, and initialisation parameter $M \in (1, 2, 5, 10)$ or random initialisation to choose a combination
441 of parameters that produces dense and separable clusters, i.e. $K = 4, L = 2, M = 2$. We also qualitatively
442 evaluate cluster centroids across all parameter settings (**Supp. Fig. 7**). Finally, we compared cluster
443 allocations over each of the 10 random trains for a set of 5,000 randomly sampled individuals held out of the
444 training splits (**Supp. Fig. 9**).

445 Once cluster centroids have been calculated, we define individual i 's soft cluster membership probability of

446 belonging to cluster k as the posterior probability of being closest in Euclidean distance to cluster k 's centroid:

$$\pi_{i,(k)} := \int \mathbb{I} \left(k = \underset{k'}{\operatorname{argmin}} \|\tilde{\mathbf{b}}_i - \mathbf{c}_{(k')}\|_2 \right) \operatorname{MVN}(\tilde{\mathbf{b}}_i \mid \mathbf{D}\mathbf{m}_i, \sigma^2 \mathbf{D}\mathbf{V}_i \mathbf{D}^T) d\tilde{\mathbf{b}}_i \quad (12)$$

447 where the second term in the integrand is the posterior from (7), and we approximate the integral in (12)
448 using 100 Monte Carlo samples from the posterior.

449 Finally, we validate the clustering by comparing cluster properties of the randomly selected 80% training set
450 used to define cluster centroids, with the held-out 20% validation set. We assign each individual to the cluster
451 for which they have highest membership probability and compare the proportion of individuals assigned to
452 each cluster, as well as distributions of sex, baseline age, number of follow-up measures, and total length of
453 follow-up of individuals assigned to each cluster. These metrics are similar across training and validation sets
454 in all strata (**Supp. Table 13**).

455 Finally we take forward bounded logit-transformed cumulative cluster probabilities to GWAS. These outputs
456 are defined as bounded logit($\pi_{i,(1)}$), bounded logit($\pi_{i,(1)} + \pi_{i,(2)}$), and bounded logit($\pi_{i,(1)} + \pi_{i,(2)} + \pi_{i,(3)}$),
457 i.e., the bounded log odds of being in the highest (k1), highest two (k1 or k2), and highest three (k1, k2 or
458 k3) weight clusters respectively. To prevent infinite log odds at $\pi \in \{0, 1\}$ we defined the following bounded
459 logit transform¹²⁰:

$$\text{bounded logit}(\pi) \equiv \text{logit} \left(\frac{(S-1)\pi + 0.5}{S} \right) \quad \pi \in [0, 1],$$

460 where $S = 100$, the number of Monte Carlo samples from the posterior in approximating (12).

461 **Genome-wide association studies**

462 **QC of UK Biobank genotyped and imputed data.** Genotyping, initial genotype QC, and imputation were
463 performed by UKBB¹¹⁰. We performed post-imputation QC to retain only bi-allelic SNPs with MAF > 0.01,
464 info score > 0.8, missing call rate < 5%, and Hardy-Weinberg equilibrium (HWE) exact test $P > 1 \times 10^{-6}$.
465 We additionally performed sample QC to exclude individuals with sex chromosome aneuploidies, whose self-
466 reported sex did not match inferred genetic sex, with an excess of third degree relatives in UKBB, identified
467 as heterozygosity or missingness outliers, excluded from autosome phasing or kinship inference, and any other
468 UKBB recommended exclusions¹¹⁰.

469 **Linear mixed model association analyses for quantitative traits.** The following association analyses are
470 all performed separately in three strata: female-specific, male-specific, and sex-combined. The intercept and
471 slope traits for GWAS, i.e. $\tilde{u}_{i,0}$ and $\tilde{u}_{i,1}$ were tested for association with genetic variants, adjusted for the
472 first 21 genetic principal components (PCs) and genotyping array, using the BOLT-LMM software⁸². A similar

473 protocol was followed for the logit-transformed soft clustering probability traits, i.e. $\pi''_{i,1}$, $\pi''_{i,2}$, and $\pi''_{i,3}$ with
474 additional adjustments for baseline trait, baseline age, (baseline age)², sex, year of birth, assessment centre,
475 number of follow-ups, and total length of follow-up (in years).

476 **Fine-mapping SNP associations** We identified putative causal variants at all GWS loci (defined by merging
477 windows of 1.5 Mb around SNPs with $P < 5 \times 10^{-8}$), using FINEMAP¹²¹ to select variants (lead SNPs) with
478 a posterior inclusion probability $> 95\%$. Lead SNPs were annotated to the nearest gene transcription start
479 site.

480 **Classifying baseline BMI and weight SNPs as reported, refined, or novel obesity associations.** We
481 curated a list of SNPs associated with any of 44 obesity-related traits in the GWAS Catalog⁵³ accessed
482 on 02 Nov 2021, henceforth referred to as “published obesity-associated variants” (**Supp. Table 1**). We
483 then conducted conditional analysis using GCTA-COJO¹²² for each lead SNP in our GWAS and published
484 obesity-associated variants within 500 kb, classifying variants as reported, refined, or novel based on previously
485 recommended criteria⁴⁴. Reported SNPs in our study are those whose effects are fully accounted for by
486 published obesity-associated variants within 500 kb. Refined SNPs fulfill all of the following criteria: (1) the
487 refined SNP is correlated (LD $r^2 \geq 0.1$) with at least one published obesity-associated variant within 500 kb,
488 (2) the refined SNP has a significantly stronger effect ($P < 0.05$ in a two-sample t-test for difference in mean
489 effect sizes) on the BMI- or weight-intercept trait than published obesity-associated SNPs and also accounts
490 for the effect of published obesity-associated SNPs in conditional analysis (conditional $P > 0.05$), and (3)
491 published obesity-associated SNPs cannot fully account for the effect of the refined SNP in conditional analysis
492 (conditional $P < 0.05$). Finally, a SNP in our study was declared novel if it was not in LD with ($r^2 < 0.1$),
493 and conditionally independent of (conditional $P < 0.05$), all published obesity-associated variants within 500
494 kb.

495 **Replication of GWS associations in UK Biobank hold-out sets**

496 **BMI and weight intercept-trait genetic associations.** We created cross-sectional obesity phenotypes for
497 the 245,447 individuals in the hold-out set for BMI and 230,861 individuals in the hold-out set for weight
498 (**Supp. Fig. 3**) by retaining the observed trait value closest to the individual’s median trait value (if multiple
499 observations present). Deterministic rank-based inverse normal transformation¹¹⁵ was applied to the residual
500 of the obesity trait adjusted for age, age², year of birth, data provider, and sex. We then tested this trait
501 for association with genetic variants, adjusted for the first 21 genetic PCs and genotyping array, using the
502 BOLT-LMM software⁸².

503 **BMI and weight slope-trait genetic associations.** We created adiposity slope phenotypes for the 17,006
504 individuals with multiple observations of BMI and 17,035 individuals with multiple observations of weight from
505 repeat assessment centre visits (**Supp. Fig. 3**) with BLUPs from linear mixed-effects models as described
506 in the slope trait modelling section above. We tested for association of this slope trait with GWS variants
507 associated with adiposity change in our discovery analyses, adjusted for the first 21 genetic PCs and genotyping
508 array, via the linear regression framework implemented in PLINK¹²³. As PLINK does not account for family
509 structure, we compared each pair of second-degree or closer related individuals (kinship coefficient > 0.0884)¹¹⁰
510 and excluded the individual in the pair having higher genotyping missingness. We repeated the same protocol
511 within each self-identified ethnic group of individuals not of white British ancestry.

512 **Genetic associations with BMI and weight cluster probabilities.** We fit regularised splines as detailed
513 above to the 17,006 individuals with multiple observations of BMI and 17,035 individuals with multiple obser-
514 vations of weight from repeat assessment centre visits (**Supp. Fig. 3**). Soft cluster membership probabilities
515 for these individuals were calculated, and the three logit-transformed π_i traits were carried forward for asso-
516 ciation testing with GWS variants associated with adiposity change in our discovery analyses. As above, we
517 pruned out second-degree or closer related individuals and performed association analysis, adjusted for baseline
518 trait, baseline age, (baseline age)², assessment centre, first 21 genetic PCs and genotyping array, via the linear
519 regression framework implemented in PLINK¹²³. We repeated the same protocol within each self-identified
520 ethnic group of individuals not of white British ancestry.

521 **Genetic associations with self-reported weight change.** We fit proportional odds logistic regression models
522 implemented in the MASS package¹²⁴ in R¹¹⁴ to estimate the additive effect of lead SNPs on self-reported one-
523 year weight change coded as an ordinal categorical variable with three levels: "loss", "no change", and "gain"
524 in 301,943 individuals (described in the data section above). All models were adjusted for BMI, age, sex, year
525 of birth, data provider, assessment centre, first 21 genetic PCs and genotyping array. We repeated the same
526 protocol within each self-identified ethnic group of individuals not of white British ancestry.

527 **Power comparison to GIANT 2019 meta-analysis of BMI**

528 We accessed publicly available summary statistics from the GIANT consortium's meta-analysis of BMI across
529 UKBB and previous GIANT releases in female-specific (max N=434,793), male-specific (max N=374,755),
530 and sex-combined strata (max N=806,834)⁴³. SNPs included in both the GIANT 2019 meta-analysis and our
531 in-house BMI-intercept GWAS that reached GWS in either study were carried forward for power comparisons,
532 resulting in 26,812 (female-specific strata), 22,123 (male-specific strata), and 82,559 (sex-combined strata)
533 SNPs. Per variant, we calculated the χ^2 statistic (as $\frac{\hat{\beta}^2}{SE^2}$) and obtained the ratio of $\chi_{in-house}^2$ to χ_{GIANT}^2 .
534 Median $\frac{\chi_{in-house}^2}{\chi_{GIANT}^2}$ across all GWS SNPs was then compared to the median ratio of sample sizes, i.e. $\frac{N_{in-house}}{N_{GIANT}}$,

535 to determine the boost in power over that expected from the sample size difference between the two studies.

536 **rs429358 single-variant analyses**

537 The following analyses were all conducted in female-specific, male-specific, and sex-combined strata.

538 **Abdominal adiposity change traits.** Slope changes in WC, WHR, WCadjBMI, and WHRadjBMI for up to
539 44,154 individuals with repeat observations were calculated using linear mixed-effects models, adjusted and
540 rank-based inverse-normal transformed¹¹⁵ for genetic association testing as described in the slope modelling
541 section above. We estimated the additive association of number of copies of the rs429358 minor allele (0, 1,
542 or 2) with slope traits adjusted for the first 21 genetic PCs and genotyping array via linear regression.

543 **Longitudinal phenome-wide association.** We curated a longitudinal research resource for 45 additional
544 quantitative phenotypes in up to 146,099 individuals of white British ancestry (**Supp. Table 14**, as identified
545 by Kuan *et al.*¹²⁵) by integrating UKBB assessment centre measurements with the interim release of primary
546 care records provided by GPs, with QC performed as described above for obesity traits. Slope changes in
547 each of these phenotypes were calculated using linear mixed-effects models described in (1). A deterministic
548 rank-based inverse normal transformation¹¹⁵, as described in (4), was applied to the slope BLUP $\hat{u}_{i,1}$. The
549 transformed slope trait was tested for additive association with number of copies of the rs429358 minor allele
550 (0, 1, or 2), adjusted for the intercept BLUP $\hat{u}_{i,0}$, baseline age, (baseline age)², sex, year of birth, number of
551 follow-ups, total length of follow-up (in years), assessment centre, first 21 genetic PCs and genotyping array.

552 **Identification of individuals with Alzheimer's or dementia diagnoses.** We identified participants with
553 codes for history or diagnosis of dementia in either primary care or hospital in-patient records (**Supp. Table 15**,
554 as identified by Kuan *et al.*¹¹²). We performed sensitivity analyses for the replication of rs429358 associations
555 with all obesity-change phenotypes after excluding up to 242 individuals of white British ancestry with recorded
556 history or diagnosis of dementia.

557 **SNP heritability and genetic correlations**

558 We estimated the heritability explained by genotyped SNPs (h_G^2) and genetic correlations (r_G) between obesity-
559 intercept and obesity-change traits, from summary statistics, using LD score regression implemented in the
560 LDSC software^{66, 126}, with pre-computed LD-scores based on European-ancestry samples of the 1000 Genomes
561 Project¹²⁷ restricted to HapMap3 SNPs⁶⁷. The same protocol was followed to determine r_G between BMI-
562 intercept in our in-house study and BMI in the GIANT 2019 meta-analysis.

563 Sex heterogeneity testing

564 We tested for sex heterogeneity in the effects of adiposity-change lead SNPs by calculating Z-statistics and
565 corresponding P-values for the difference in female-specific and male-specific effects as:

$$Z_{sexhet} = \frac{(\hat{\beta}_{(F)} - \hat{\beta}_{(M)})}{\sqrt{(SE_{(F)}^2 + SE_{(M)}^2)}}$$

566 A similar statistic and test was used to determine heterogeneity between (h_G^2) of all traits in males and females,
567 and r_G between obesity-intercepts and obesity-change traits in males and females.

568 Data and code availability

569 All generated summary statistics from GWAS will be made publicly available through the GWAS Catalog⁵³
570 upon publication. All code required to reproduce analyses are publicly available at: [https://github.com/
571 lindgengroup/longitudinal_primarycare/tree/main/adiposity/scripts/manuscript](https://github.com/lindgengroup/longitudinal_primarycare/tree/main/adiposity/scripts/manuscript).

572 Acknowledgements

573 S.S.V. is supported by the Rhodes Scholarship, Clarendon Fund, and the Medical Sciences Doctoral Train-
574 ing Centre at the University of Oxford. K.C. is supported by the University of Leicester (College of Life
575 Sciences) and Health Data Research UK. L.B.L.W. is supported by the Wellcome Trust (221651/Z/20/Z).
576 C.H. is supported by the Alan Turing Institute, the EPSRC grant Bayes4Health, Novartis, and Novo Nordisk.
577 C.M.L. is supported by the Li Ka Shing Foundation, NIHR Oxford Biomedical Research Centre, Oxford, NIH
578 (1P50HD104224-01), Gates Foundation (INV-024200), and a Wellcome Trust Investigator Award (221782/Z/20/Z).
579 The research was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with additional
580 support from the NIHR Oxford BRC. This research has been conducted using the UK Biobank Resource under
581 Application Number 10844. The views expressed are those of the authors and not necessarily those of the
582 NHS, the NIHR or the Department of Health.

583 Competing Interests

584 C.H. reports grants from Novo Nordisk and Novartis; C.M.L. reports grants from Bayer AG and Novo Nordisk
585 and has a partner who works at Vertex. The other authors declare no conflicts of interest.

References

- ¹ Bluher, M. Obesity: global epidemiology and pathogenesis. *Nat Rev Endocrinol* **15**, 288–298 (2019). URL <https://www.ncbi.nlm.nih.gov/pubmed/30814686>.
- ² Collaborators, G. B. D. O. *et al.* Health effects of overweight and obesity in 195 countries over 25 years. *N Engl J Med* **377**, 13–27 (2017). URL <https://www.ncbi.nlm.nih.gov/pubmed/28604169>.
- ³ Must, A. *et al.* The disease burden associated with overweight and obesity. *JAMA* **282**, 1523–9 (1999). URL <https://www.ncbi.nlm.nih.gov/pubmed/10546691>.
- ⁴ Loos, R. J. F. & Yeo, G. S. H. The genetics of obesity: from discovery to biology. *Nat Rev Genet* **23**, 120–133 (2022). URL <https://www.ncbi.nlm.nih.gov/pubmed/34556834>.
- ⁵ Maes, H. H., Neale, M. C. & Eaves, L. J. Genetic and environmental factors in relative body weight and human adiposity. *Behav Genet* **27**, 325–51 (1997). URL <https://www.ncbi.nlm.nih.gov/pubmed/9519560>.
- ⁶ Elks, C. E. *et al.* Variability in the heritability of body mass index: a systematic review and meta-regression. *Front Endocrinol (Lausanne)* **3**, 29 (2012). URL <https://www.ncbi.nlm.nih.gov/pubmed/22645519>.
- ⁷ Khera, A. V. *et al.* Polygenic prediction of weight and obesity trajectories from birth to adulthood. *Cell* **177**, 587–596 e9 (2019). URL <https://www.ncbi.nlm.nih.gov/pubmed/31002795>.
- ⁸ Hardy, R. *et al.* Life course variations in the associations between fto and mc4r gene variants and body size. *Hum Mol Genet* **19**, 545–52 (2010). URL <https://www.ncbi.nlm.nih.gov/pubmed/19880856>.
- ⁹ Silventoinen, K. *et al.* Changing genetic architecture of body mass index from infancy to early adulthood: an individual based pooled analysis of 25 twin cohorts. *Int J Obes (Lond)* **46**, 1901–1909 (2022). URL <https://www.ncbi.nlm.nih.gov/pubmed/35945263>.
- ¹⁰ Helgeland, O. *et al.* Characterization of the genetic architecture of infant and early childhood body mass index. *Nat Metab* **4**, 344–358 (2022). URL <https://www.ncbi.nlm.nih.gov/pubmed/35315439>.
- ¹¹ Couto Alves, A. *et al.* Gwas on longitudinal growth traits reveals different genetic factors influencing infant, child, and adult bmi. *Sci Adv* **5**, eaaw3095 (2019). URL <https://www.ncbi.nlm.nih.gov/pubmed/31840077>.
- ¹² Hjelmborg, J. *et al.* Genetic influences on growth traits of bmi: a longitudinal study of adult twins. *Obesity (Silver Spring)* **16**, 847–52 (2008). URL <https://www.ncbi.nlm.nih.gov/pubmed/18239571>.
- ¹³ Fabsitz, R. R., Sholinsky, P. & Carmelli, D. Genetic influences on adult weight gain and maximum body mass index in male twins. *Am J Epidemiol* **140**, 711–20 (1994). URL <https://www.ncbi.nlm.nih.gov/pubmed/7942773>.
- ¹⁴ Austin, M. A. *et al.* Genetic influences on changes in body mass index: a longitudinal analysis of women twins. *Obes Res* **5**, 326–31 (1997). URL <https://www.ncbi.nlm.nih.gov/pubmed/9285839>.
- ¹⁵ Xu, J. *et al.* Exploring the clinical and genetic associations of adult weight trajectories using electronic health records in a racially diverse biobank: a phenome-wide and polygenic risk study. *Lancet Digit Health* **4**, e604–e614 (2022). URL <https://www.ncbi.nlm.nih.gov/pubmed/35780037>.
- ¹⁶ Shilo, S., Rossman, H. & Segal, E. Axes of a revolution: challenges and promises of big data in healthcare. *Nat Med* **26**, 29–38 (2020). URL <https://www.ncbi.nlm.nih.gov/pubmed/31932803>.
- ¹⁷ Wolford, B. N., Willer, C. J. & Surakka, I. Electronic health records: the next wave of complex disease genetics. *Hum Mol Genet* **27**, R14–R21 (2018). URL <https://www.ncbi.nlm.nih.gov/pubmed/29547983>.
- ¹⁸ Wei, W. Q. & Denny, J. C. Extracting research-quality phenotypes from electronic health records to support precision medicine. *Genome Med* **7**, 41 (2015). URL <https://www.ncbi.nlm.nih.gov/pubmed/25937834>.
- ¹⁹ Gottesman, O. *et al.* The electronic medical records and genomics (emerge) network: past, present, and future. *Genet Med* **15**, 761–71 (2013). URL <https://www.ncbi.nlm.nih.gov/pubmed/23743551>.

- ²⁰ Monda, K. L. *et al.* A meta-analysis identifies new loci associated with body mass index in individuals of african ancestry. *Nat Genet* **45**, 690–6 (2013). URL <https://www.ncbi.nlm.nih.gov/pubmed/23583978>.
- ²¹ Postmus, I. *et al.* Pharmacogenetic meta-analysis of genome-wide association studies of ldl cholesterol response to statins. *Nat Commun* **5**, 5068 (2014). URL <https://www.ncbi.nlm.nih.gov/pubmed/25350695>.
- ²² Chiu, Y. F., Justice, A. E. & Melton, P. E. Longitudinal analytical approaches to genetic data. *BMC Genet* **17 Suppl 2**, 4 (2016). URL <https://www.ncbi.nlm.nih.gov/pubmed/26866891>.
- ²³ Fan, R. *et al.* Longitudinal association analysis of quantitative traits. *Genet Epidemiol* **36**, 856–69 (2012). URL <https://www.ncbi.nlm.nih.gov/pubmed/22965819>.
- ²⁴ Furlotte, N. A., Eskin, E. & Eyheramendy, S. Genome-Wide Association Mapping With Longitudinal Data. *Genetic Epidemiology* **36**, 463–471 (2012). URL <https://onlinelibrary.wiley.com/doi/abs/10.1002/gepi.21640>. _eprint: <https://onlinelibrary.wiley.com/doi/pdf/10.1002/gepi.21640>.
- ²⁵ Goldstein, J. A. *et al.* Labwas: Novel findings and study design recommendations from a meta-analysis of clinical labs in two independent biobanks. *PLoS Genet* **16**, e1009077 (2020). URL <https://www.ncbi.nlm.nih.gov/pubmed/33175840>.
- ²⁶ Justice, A. E. *et al.* Genome-wide association of trajectories of systolic blood pressure change. *BMC Proc* **10**, 321–327 (2016). URL <https://www.ncbi.nlm.nih.gov/pubmed/27980656>.
- ²⁷ Gauderman, W. J. *et al.* Longitudinal data analysis in pedigree studies. *Genet Epidemiol* **25 Suppl 1**, S18–28 (2003). URL <https://www.ncbi.nlm.nih.gov/pubmed/14635165>.
- ²⁸ Ko, S. *et al.* Gwas of longitudinal trajectories at biobank scale. *Am J Hum Genet* **109**, 433–445 (2022). URL <https://www.ncbi.nlm.nih.gov/pubmed/35196515>.
- ²⁹ Laird, N. M. & Ware, J. H. Random-Effects Models for Longitudinal Data. *Biometrics* **38**, 963–974 (1982). URL <https://www.jstor.org/stable/2529876>. Publisher: [Wiley, International Biometric Society].
- ³⁰ Xu, H. *et al.* High-throughput and efficient multilocus genome-wide association study on longitudinal outcomes. *Bioinformatics* **36**, 3004–3010 (2020). URL <https://doi.org/10.1093/bioinformatics/btaa120>.
- ³¹ Ruppert, D., Wand, M. P. & Carroll, R. J. *Semiparametric Regression*. Cambridge Series in Statistical and Probabilistic Mathematics (Cambridge University Press, Cambridge, 2003). URL <https://www.cambridge.org/core/books/semiparametric-regression/02FC9A9435232CA67532B4D31874412C>.
- ³² Das, K. *et al.* A dynamic model for genome-wide association studies. *Human Genetics* **129**, 629–639 (2011). URL <https://doi.org/10.1007/s00439-011-0960-6>.
- ³³ Das, K. *et al.* Dynamic semiparametric Bayesian models for genetic mapping of complex trait with irregular longitudinal data. *Statistics in Medicine* **32**, 509–523 (2013). URL <https://onlinelibrary.wiley.com/doi/abs/10.1002/sim.5535>. _eprint: <https://onlinelibrary.wiley.com/doi/pdf/10.1002/sim.5535>.
- ³⁴ Li, Z. & Sillanpää, M. J. A Bayesian Nonparametric Approach for Mapping Dynamic Quantitative Traits. *Genetics* **194**, 997–1016 (2013). URL <https://doi.org/10.1534/genetics.113.152736>.
- ³⁵ Li, J., Wang, Z., Li, R. & Wu, R. BAYESIAN GROUP LASSO FOR NONPARAMETRIC VARYING-COEFFICIENT MODELS WITH APPLICATION TO FUNCTIONAL GENOME-WIDE ASSOCIATION STUDIES. *The annals of applied statistics* **9**, 640–664 (2015). URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605444/>.
- ³⁶ Anh Luong, D. T. & Chandola, V. A K-Means Approach to Clustering Disease Progressions. In *2017 IEEE International Conference on Healthcare Informatics (ICHI)*, 268–274 (2017).
- ³⁷ Hedman, A. K. *et al.* Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning. *Heart* **106**, 342–349 (2020). URL <https://heart.bmj.com/content/106/5/342>. Publisher: BMJ Publishing Group Ltd and British Cardiovascular Society Section: Heart failure and cardiomyopathies.
- ³⁸ Lee, C. & Schaar, M. V. D. Temporal Phenotyping using Deep Predictive Clustering of Disease Progression. In *Proceedings of the 37th International Conference on Machine Learning*, 5767–5777 (PMLR, 2020). URL <https://proceedings.mlr.press/v119/lee20h.html>. ISSN: 2640-3498.

- ³⁹ Mullin, S. *et al.* Longitudinal K-means approaches to clustering and analyzing EHR opioid use trajectories for clinical subtypes. *Journal of Biomedical Informatics* **122**, 103889 (2021). URL <https://www.sciencedirect.com/science/article/pii/S1532046421002185>.
- ⁴⁰ Lee, C., Rashbass, J. & van der Schaar, M. Outcome-Oriented Deep Temporal Phenotyping of Disease Progression. *IEEE Transactions on Biomedical Engineering* **68**, 2423–2434 (2021). Conference Name: IEEE Transactions on Biomedical Engineering.
- ⁴¹ Carr, O., Javer, A., Rockenschaub, P., Parsons, O. & Durichen, R. Longitudinal patient stratification of electronic health records with flexible adjustment for clinical outcomes. In *Proceedings of Machine Learning for Health*, 220–238 (PMLR, 2021). URL <https://proceedings.mlr.press/v158/carr21a.html>. ISSN: 2640-3498.
- ⁴² Sudlow, C. *et al.* Uk biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* **12**, e1001779 (2015). URL <https://www.ncbi.nlm.nih.gov/pubmed/25826379>.
- ⁴³ Pulit, S. L. *et al.* Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of european ancestry. *Hum Mol Genet* **28**, 166–174 (2019). URL <https://www.ncbi.nlm.nih.gov/pubmed/30239722>.
- ⁴⁴ Benonisdottir, S. *et al.* Epigenetic and genetic components of height regulation. *Nat Commun* **7**, 13490 (2016). URL <https://www.ncbi.nlm.nih.gov/pubmed/27848971>.
- ⁴⁵ Mo, D. *et al.* Transcriptome landscape of porcine intramuscular adipocytes during differentiation. *J Agric Food Chem* **65**, 6317–6328 (2017). URL <https://www.ncbi.nlm.nih.gov/pubmed/28673084>.
- ⁴⁶ Tews, D. *et al.* Teneurin-2 (tenm2) deficiency induces ucpl expression in differentiating human fat cells. *Mol Cell Endocrinol* **443**, 106–113 (2017). URL <https://www.ncbi.nlm.nih.gov/pubmed/28088466>.
- ⁴⁷ Han, Y. *et al.* Plasma cholinesterase is associated with chinese adolescent overweight or obesity and metabolic syndrome prediction. *Diabetes Metab Syndr Obes* **12**, 685–702 (2019). URL <https://www.ncbi.nlm.nih.gov/pubmed/31190929>.
- ⁴⁸ Valle-Martos, R. *et al.* Liver enzymes correlate with metabolic syndrome, inflammation, and endothelial dysfunction in prepubertal children with obesity. *Front Pediatr* **9**, 629346 (2021). URL <https://www.ncbi.nlm.nih.gov/pubmed/33665176>.
- ⁴⁹ Chen, V. P., Gao, Y., Geng, L. & Brimijoin, S. Butyrylcholinesterase regulates central ghrelin signaling and has an impact on food intake and glucose homeostasis. *Int J Obes (Lond)* **41**, 1413–1419 (2017). URL <https://www.ncbi.nlm.nih.gov/pubmed/28529331>.
- ⁵⁰ Jung, H. *et al.* Sexually dimorphic behavior, neuronal activity, and gene expression in chd8-mutant mice. *Nat Neurosci* **21**, 1218–1228 (2018). URL <https://www.ncbi.nlm.nih.gov/pubmed/30104731>.
- ⁵¹ Tian, M., Shinkura, R., Shinkura, N. & Alt, F. W. Growth retardation, early death, and dna repair defects in mice deficient for the nucleotide excision repair enzyme xpf. *Mol Cell Biol* **24**, 1200–5 (2004). URL <https://www.ncbi.nlm.nih.gov/pubmed/14729965>.
- ⁵² Pirastu, N. *et al.* Genetic analyses identify widespread sex-differential participation bias. *Nat Genet* **53**, 663–671 (2021). URL <https://www.ncbi.nlm.nih.gov/pubmed/33888908>.
- ⁵³ Welter, D. *et al.* The nhgri gwas catalog, a curated resource of snp-trait associations. *Nucleic Acids Res* **42**, D1001–6 (2014). URL <https://www.ncbi.nlm.nih.gov/pubmed/24316577>.
- ⁵⁴ Reynolds, A. P., Richards, G., de la Iglesia, B. & Rayward-Smith, V. J. Clustering Rules: A Comparison of Partitioning and Hierarchical Clustering Algorithms. *Journal of Mathematical Modelling and Algorithms* **5**, 475–504 (2006). URL <https://doi.org/10.1007/s10852-005-9022-1>.
- ⁵⁵ Schubert, E. & Rousseeuw, P. J. Faster k-Medoids Clustering: Improving the PAM, CLARA, and CLARANS Algorithms. In Amato, G., Gennaro, C., Oria, V. & Radovanović, M. (eds.) *Similarity Search and Applications*, Lecture Notes in Computer Science, 171–187 (Springer International Publishing, Cham, 2019).
- ⁵⁶ Surakka, I. *et al.* The impact of low-frequency and rare variants on lipid levels. *Nat Genet* **47**, 589–97 (2015). URL <https://www.ncbi.nlm.nih.gov/pubmed/25961943>.
- ⁵⁷ Hoffmann, T. J. *et al.* A large electronic-health-record-based genome-wide study of serum lipids. *Nat Genet* **50**, 401–413 (2018). URL <https://www.ncbi.nlm.nih.gov/pubmed/29507422>.

- ⁵⁸ Shen, L. *et al.* Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in mci and ad: A study of the adni cohort. *Neuroimage* **53**, 1051–63 (2010). URL <https://www.ncbi.nlm.nih.gov/pubmed/20100581>.
- ⁵⁹ Nazarian, A., Yashin, A. I. & Kulminski, A. M. Genome-wide analysis of genetic predisposition to alzheimer's disease and related sex disparities. *Alzheimers Res Ther* **11**, 5 (2019). URL <https://www.ncbi.nlm.nih.gov/pubmed/30636644>.
- ⁶⁰ Joshi, P. K. *et al.* Variants near chrna3/5 and apoe have age- and sex-related effects on human lifespan. *Nat Commun* **7**, 11174 (2016). URL <https://www.ncbi.nlm.nih.gov/pubmed/27029810>.
- ⁶¹ Pilling, L. C. *et al.* Human longevity: 25 genetic loci associated in 389,166 uk biobank participants. *Aging (Albany NY)* **9**, 2504–2520 (2017). URL <https://www.ncbi.nlm.nih.gov/pubmed/29227965>.
- ⁶² Lumsden, A. L., Mulugeta, A., Zhou, A. & Hypponen, E. Apolipoprotein e (apoe) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the uk biobank. *EBioMedicine* **59**, 102954 (2020). URL <https://www.ncbi.nlm.nih.gov/pubmed/32818802>.
- ⁶³ Astle, W. J. *et al.* The allelic landscape of human blood cell trait variation and links to common complex disease. *Cell* **167**, 1415–1429 e19 (2016). URL <https://www.ncbi.nlm.nih.gov/pubmed/27863252>.
- ⁶⁴ Kettunen, J. *et al.* Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of lpa. *Nat Commun* **7**, 11122 (2016). URL <https://www.ncbi.nlm.nih.gov/pubmed/27005778>.
- ⁶⁵ Shrine, N. *et al.* New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. *Nat Genet* **51**, 481–493 (2019). URL <https://www.ncbi.nlm.nih.gov/pubmed/30804560>.
- ⁶⁶ Bulik-Sullivan, B. K. *et al.* Ld score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–5 (2015). URL <https://www.ncbi.nlm.nih.gov/pubmed/25642630>.
- ⁶⁷ International HapMap, C. *et al.* Integrating common and rare genetic variation in diverse human populations. *Nature* **467**, 52–8 (2010). URL <https://www.ncbi.nlm.nih.gov/pubmed/20811451>.
- ⁶⁸ Song, M. *et al.* Associations between genetic variants associated with body mass index and trajectories of body fatness across the life course: a longitudinal analysis. *Int J Epidemiol* **47**, 506–515 (2018). URL <https://www.ncbi.nlm.nih.gov/pubmed/29211904>.
- ⁶⁹ Bray, M. S. *et al.* Nih working group report-using genomic information to guide weight management: From universal to precision treatment. *Obesity (Silver Spring)* **24**, 14–22 (2016). URL <https://www.ncbi.nlm.nih.gov/pubmed/26692578>.
- ⁷⁰ Delahanty, L. M. *et al.* Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the diabetes prevention program. *Diabetes Care* **35**, 363–6 (2012). URL <https://www.ncbi.nlm.nih.gov/pubmed/22179955>.
- ⁷¹ Delahanty, L. M. *et al.* Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the diabetes prevention program. *Diabetes Care* **35**, 363–6 (2012). URL <https://www.ncbi.nlm.nih.gov/pubmed/22179955>.
- ⁷² Liou, T. H. *et al.* Esr1, fto, and ucp2 genes interact with bariatric surgery affecting weight loss and glycemic control in severely obese patients. *Obes Surg* **21**, 1758–65 (2011). URL <https://www.ncbi.nlm.nih.gov/pubmed/21720911>.
- ⁷³ Sarzynski, M. A. *et al.* Associations of markers in 11 obesity candidate genes with maximal weight loss and weight regain in the sos bariatric surgery cases. *Int J Obes (Lond)* **35**, 676–83 (2011). URL <https://www.ncbi.nlm.nih.gov/pubmed/20733583>.
- ⁷⁴ Zhang, X. *et al.* Fto genotype and 2-year change in body composition and fat distribution in response to weight-loss diets: the pounds lost trial. *Diabetes* **61**, 3005–11 (2012). URL <https://www.ncbi.nlm.nih.gov/pubmed/22891219>.
- ⁷⁵ Papandonatos, G. D. *et al.* Genetic predisposition to weight loss and regain with lifestyle intervention: Analyses from the diabetes prevention program and the look ahead randomized controlled trials. *Diabetes* **64**, 4312–21 (2015). URL <https://www.ncbi.nlm.nih.gov/pubmed/26253612>.

- ⁷⁶ McCaffery, J. M. *et al.* Genetic predictors of change in waist circumference and waist-to-hip ratio with lifestyle intervention: The trans-nih consortium for genetics of weight loss response to lifestyle intervention. *Diabetes* **71**, 669–676 (2022). URL <https://www.ncbi.nlm.nih.gov/pubmed/35043141>.
- ⁷⁷ Holzapfel, C. *et al.* Association between single nucleotide polymorphisms and weight reduction in behavioural interventions—a pooled analysis. *Nutrients* **13** (2021). URL <https://www.ncbi.nlm.nih.gov/pubmed/33801339>.
- ⁷⁸ Nelson, M. R. *et al.* The support of human genetic evidence for approved drug indications. *Nat Genet* **47**, 856–60 (2015). URL <https://www.ncbi.nlm.nih.gov/pubmed/26121088>.
- ⁷⁹ Beesley, L. J., Fritsche, L. G. & Mukherjee, B. A modeling framework for exploring sampling and observation process biases in genome and phenome-wide association studies using electronic health records. *bioRxiv* (2019). URL <https://www.biorxiv.org/content/early/2019/05/14/499392>. <https://www.biorxiv.org/content/early/2019/05/14/499392.full.pdf>.
- ⁸⁰ Fry, A. *et al.* Comparison of sociodemographic and health-related characteristics of uk biobank participants with those of the general population. *Am J Epidemiol* **186**, 1026–1034 (2017). URL <https://www.ncbi.nlm.nih.gov/pubmed/28641372>.
- ⁸¹ Goudie, R. J. B., Presanis, A. M., Lunn, D., Angelis, D. D. & Wernisch, L. Joining and Splitting Models with Markov Melding. *Bayesian Analysis* **14**, 81–109 (2019). URL <https://projecteuclid.org/journals/bayesian-analysis/volume-14/issue-1/Joining-and-Splitting-Models-with-Markov-Melding/10.1214/18-BA1104.full>. Publisher: International Society for Bayesian Analysis.
- ⁸² Loh, P. R. *et al.* Efficient bayesian mixed-model analysis increases association power in large cohorts. *Nat Genet* **47**, 284–90 (2015). URL <https://www.ncbi.nlm.nih.gov/pubmed/25642633>.
- ⁸³ Li, H. *et al.* Triglyceride-glucose index variability and incident cardiovascular disease: a prospective cohort study. *Cardiovasc Diabetol* **21**, 105 (2022). URL <https://www.ncbi.nlm.nih.gov/pubmed/35689232>.
- ⁸⁴ Nuyujukian, D. S. *et al.* Blood pressure variability and risk of heart failure in accord and the vadt. *Diabetes Care* **43**, 1471–1478 (2020). URL <https://www.ncbi.nlm.nih.gov/pubmed/32327422>.
- ⁸⁵ Speakman, J. R. *et al.* Set points, settling points and some alternative models: theoretical options to understand how genes and environments combine to regulate body adiposity. *Dis Model Mech* **4**, 733–45 (2011). URL <https://www.ncbi.nlm.nih.gov/pubmed/22065844>.
- ⁸⁶ Muller, M. J., Geisler, C., Heymsfield, S. B. & Bosy-Westphal, A. Recent advances in understanding body weight homeostasis in humans. *F1000Res* **7** (2018). URL <https://www.ncbi.nlm.nih.gov/pubmed/30026913>.
- ⁸⁷ Nawaz, H., Chan, W., Abdulrahman, M., Larson, D. & Katz, D. L. Self-reported weight and height: implications for obesity research. *Am J Prev Med* **20**, 294–8 (2001). URL <https://www.ncbi.nlm.nih.gov/pubmed/11331120>.
- ⁸⁸ Kowal, R. C., Herz, J., Goldstein, J. L., Esser, V. & Brown, M. S. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein e-enriched lipoproteins. *Proc Natl Acad Sci U S A* **86**, 5810–4 (1989). URL <https://www.ncbi.nlm.nih.gov/pubmed/2762297>.
- ⁸⁹ Kockx, M., Traini, M. & Kritharides, L. Cell-specific production, secretion, and function of apolipoprotein e. *J Mol Med (Berl)* **96**, 361–371 (2018). URL <https://www.ncbi.nlm.nih.gov/pubmed/29516132>.
- ⁹⁰ Garrison, R. J. *et al.* Obesity and lipoprotein cholesterol in the framingham offspring study. *Metabolism* **29**, 1053–60 (1980). URL <https://www.ncbi.nlm.nih.gov/pubmed/7432169>.
- ⁹¹ Albrink, M. J. *et al.* Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population. *Lipids* **15**, 668–76 (1980). URL <https://www.ncbi.nlm.nih.gov/pubmed/7421421>.
- ⁹² Panagiotakos, D. B., Pitsavos, C., Yannakoulia, M., Chrysohoou, C. & Stefanadis, C. The implication of obesity and central fat on markers of chronic inflammation: The attica study. *Atherosclerosis* **183**, 308–15 (2005). URL <https://www.ncbi.nlm.nih.gov/pubmed/16285994>.
- ⁹³ Purdy, J. C. & Shatzel, J. J. The hematologic consequences of obesity. *Eur J Haematol* **106**, 306–319 (2021). URL <https://www.ncbi.nlm.nih.gov/pubmed/33270290>.

- ⁹⁴ Cai, X. *et al.* Potassium and obesity/metabolic syndrome: A systematic review and meta-analysis of the epidemiological evidence. *Nutrients* **8**, 183 (2016). URL <https://www.ncbi.nlm.nih.gov/pubmed/27023597>.
- ⁹⁵ Gillette Guyonnet, S. *et al.* Iana (international academy on nutrition and aging) expert group: weight loss and alzheimer's disease. *J Nutr Health Aging* **11**, 38–48 (2007). URL <https://www.ncbi.nlm.nih.gov/pubmed/17315079>.
- ⁹⁶ von Hardenberg, S., Gnewuch, C., Schmitz, G. & Borlak, J. Apoe is a major determinant of hepatic bile acid homeostasis in mice. *J Nutr Biochem* **52**, 82–91 (2018). URL <https://www.ncbi.nlm.nih.gov/pubmed/29175670>.
- ⁹⁷ Wang, J. *et al.* Apoe and the role of very low density lipoproteins in adipose tissue inflammation. *Atherosclerosis* **223**, 342–9 (2012). URL <https://www.ncbi.nlm.nih.gov/pubmed/22770993>.
- ⁹⁸ Blanchard, J. W. *et al.* Apoe4 impairs myelination via cholesterol dysregulation in oligodendrocytes. *Nature* **611**, 769–779 (2022). URL <https://www.ncbi.nlm.nih.gov/pubmed/36385529>.
- ⁹⁹ Greendale, G. A. *et al.* Changes in body composition and weight during the menopause transition. *JCI Insight* **4** (2019). URL <https://www.ncbi.nlm.nih.gov/pubmed/30843880>.
- ¹⁰⁰ Davies, K. M., Heaney, R. P., Recker, R. R., Barger-Lux, M. J. & Lappe, J. M. Hormones, weight change and menopause. *Int J Obes Relat Metab Disord* **25**, 874–9 (2001). URL <https://www.ncbi.nlm.nih.gov/pubmed/11439302>.
- ¹⁰¹ Chen, Y. W., Hang, D., Kvaerner, A. S., Giovannucci, E. & Song, M. Associations between body shape across the life course and adulthood concentrations of sex hormones in men and pre- and postmenopausal women: a multicohort study. *Br J Nutr* **127**, 1000–1009 (2022). URL <https://www.ncbi.nlm.nih.gov/pubmed/34187605>.
- ¹⁰² Conroy, M. *et al.* The advantages of uk biobank's open-access strategy for health research. *J Intern Med* **286**, 389–397 (2019). URL <https://www.ncbi.nlm.nih.gov/pubmed/31283063>.
- ¹⁰³ Coady, S. A. *et al.* Genetic variability of adult body mass index: a longitudinal assessment in framingham families. *Obes Res* **10**, 675–81 (2002). URL <https://www.ncbi.nlm.nih.gov/pubmed/12105290>.
- ¹⁰⁴ Singh, P. *et al.* Statins decrease leptin expression in human white adipocytes. *Physiol Rep* **6** (2018). URL <https://www.ncbi.nlm.nih.gov/pubmed/29372612>.
- ¹⁰⁵ McCarron, D. A. & Reusser, M. E. Body weight and blood pressure regulation. *Am J Clin Nutr* **63**, 423S–425S (1996). URL <https://www.ncbi.nlm.nih.gov/pubmed/8615333>.
- ¹⁰⁶ Hernan, M. A., Hernandez-Diaz, S. & Robins, J. M. A structural approach to selection bias. *Epidemiology* **15**, 615–25 (2004). URL <https://www.ncbi.nlm.nih.gov/pubmed/15308962>.
- ¹⁰⁷ Beesley, L. J. *et al.* The emerging landscape of health research based on biobanks linked to electronic health records: Existing resources, statistical challenges, and potential opportunities. *Stat Med* **39**, 773–800 (2020). URL <https://www.ncbi.nlm.nih.gov/pubmed/31859414>.
- ¹⁰⁸ Kutcher, S. A., Brophy, J. M., Banack, H. R., Kaufman, J. S. & Samuel, M. Emulating a randomised controlled trial with observational data: An introduction to the target trial framework. *Can J Cardiol* **37**, 1365–1377 (2021). URL <https://www.ncbi.nlm.nih.gov/pubmed/34090982>.
- ¹⁰⁹ Shortreed, S. M., Rutter, C. M., Cook, A. J. & Simon, G. E. Improving pragmatic clinical trial design using real-world data. *Clin Trials* **16**, 273–282 (2019). URL <https://www.ncbi.nlm.nih.gov/pubmed/30866672>.
- ¹¹⁰ Bycroft, C. *et al.* The uk biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018). URL <https://www.ncbi.nlm.nih.gov/pubmed/30305743>.
- ¹¹¹ Team, U. B. *UK Biobank Primary Care Linked Data* (2019), version 1.0 edn. URL https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/primary_care_data.pdf.
- ¹¹² Kuan, V. *et al.* A chronological map of 308 physical and mental health conditions from 4 million individuals in the english national health service. *Lancet Digit Health* **1**, e63–e77 (2019). URL <https://www.ncbi.nlm.nih.gov/pubmed/31650125>.

- ¹¹³ Bates, D., Machler, M., Bolker, B. & S., W. Fitting linear mixed-effects models using lme4. *Journal of Statistical Software* **67**, 1–48 (2015). URL <https://doi.org/10.18637/jss.v067.i01>.
- ¹¹⁴ R Core Team. *R: A Language and Environment for Statistical Computing* (R Foundation for Statistical Computing, Vienna, Austria, 2021). URL <https://www.R-project.org/>.
- ¹¹⁵ Beasley, T. M., Erickson, S. & Allison, D. B. Rank-Based Inverse Normal Transformations are Increasingly Used, But are They Merited? *Behavior Genetics* **39**, 580–595 (2009). URL <https://doi.org/10.1007/s10519-009-9281-0>.
- ¹¹⁶ Eilers, P. H. C. & Marx, B. D. Flexible smoothing with B-splines and penalties. *Statistical Science* **11**, 89–121 (1996). URL <https://projecteuclid.org/journals/statistical-science/volume-11/issue-2/Flexible-smoothing-with-B-splines-and-penalties/10.1214/ss/1038425655.full>. Publisher: Institute of Mathematical Statistics.
- ¹¹⁷ O’Hagan, A. & Kendall, M. G. *Kendall’s Advanced Theory of Statistics: Bayesian inference. Volume 2B* (Edward Arnold, 1994). Google-Books-ID: DlrEMgEACAAJ.
- ¹¹⁸ Maechler, M., Rousseeuw, P., Struyf, A., Hubert, M. & Hornik, K. *cluster: Cluster Analysis Basics and Extensions* (2022). URL <https://CRAN.R-project.org/package=cluster>. R package version 2.1.4 — For new features, see the ‘Changelog’ file (in the package source).
- ¹¹⁹ Peter, J. R. Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. *Journal of Computational and Applied Mathematics* **20**, 53–65 (1987). URL <https://www.sciencedirect.com/science/article/pii/0377042787901257>.
- ¹²⁰ Smithson, M. & Verkuilen, J. A better lemon squeezer? maximum-likelihood regression with beta-distributed dependent variables. *Psychol Methods* **11**, 54–71 (2006). URL <https://www.ncbi.nlm.nih.gov/pubmed/16594767>.
- ¹²¹ Benner, C. *et al.* Finemap: efficient variable selection using summary data from genome-wide association studies. *Bioinformatics* **32**, 1493–501 (2016). URL <https://www.ncbi.nlm.nih.gov/pubmed/26773131>.
- ¹²² Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. Gcta: a tool for genome-wide complex trait analysis. *Am J Hum Genet* **88**, 76–82 (2011). URL <https://www.ncbi.nlm.nih.gov/pubmed/21167468>.
- ¹²³ Chang, C. C. *et al.* Second-generation plink: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015). URL <https://www.ncbi.nlm.nih.gov/pubmed/25722852>.
- ¹²⁴ Venables, W. N. & Ripley, B. D. *Modern Applied Statistics with S* (Springer, New York, 2002), fourth edn. URL <https://www.stats.ox.ac.uk/pub/MASS4/>. ISBN 0-387-95457-0.
- ¹²⁵ Denaxas, S. *et al.* A semi-supervised approach for rapidly creating clinical biomarker phenotypes in the uk biobank using different primary care ehr and clinical terminology systems. *JAMIA Open* **3**, 545–556 (2020). URL <https://www.ncbi.nlm.nih.gov/pubmed/33619467>.
- ¹²⁶ Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat Genet* **47**, 1236–41 (2015). URL <https://www.ncbi.nlm.nih.gov/pubmed/26414676>.
- ¹²⁷ Genomes Project, C. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74 (2015). URL <https://www.ncbi.nlm.nih.gov/pubmed/26432245>.

Table 1: Characterisation of obesity trait data in longitudinal records curated from UK Biobank assessment centre visits and linked general practitioner (GP) records. BMI = body mass index, obs. = observation, S.D. = standard deviation, I.Q.R. = inter-quartile range

| Trait | Sex | Number of individuals | Number of obs. | Mean number of repeat obs. (SD) | Mean length of follow-up, years (SD) | Mean age at first obs., years (SD) | Median trait value at first obs. (IQR) |
|------------------------|-----|-----------------------|----------------|---------------------------------|--------------------------------------|------------------------------------|--|
| BMI, kg/m ² | F | 88,243 (54.4%) | 696,984 | 7.90 (7.34) | 13.7 (6.63) | 48.6 (9.68) | 24.6 (22.2, 27.9) |
| BMI, kg/m ² | M | 73,965 (45.6%) | 581,161 | 7.86 (7.12) | 12.8 (6.55) | 50.1 (9.59) | 26.1 (24.0, 28.7) |
| Weight, kg | F | 96,625 (54.6%) | 816,885 | 8.45 (8.33) | 13.9 (6.62) | 48.3 (9.63) | 65.0 (59.0, 74.0) |
| Weight, kg | M | 80,473 (45.4%) | 666,258 | 8.28 (7.82) | 12.9 (6.57) | 50.0 (9.57) | 81.6 (73.8, 90.0) |




Figure 2: Genome-wide novel and refined SNP associations with baseline obesity estimated over the measurement window for each individual. (A) Combined Manhattan plot displaying genome-wide SNP associations with obesity trait (BMI or weight) across female, male, and sex-combined analysis strata. Each point represents a SNP, with GWS SNPs ($P < 5 \times 10^{-8}$) coloured in: green for previously published obesity associations, blue for SNPs in linkage disequilibrium (LD) ($r^2 > 0.1$) with published associations, yellow for refined SNPs that represent conditionally independent ($P_{conditional} < 0.05$) and stronger associations with baseline obesity than published SNPs in the region, and pink for novel associations (see Methods⁴⁴). Novel SNPs are annotated to their nearest gene. **(B)** Proportion of variance in baseline BMI and weight that can be explained by the fine-mapped independent lead SNPs in each strata. In green is the proportion of variance explained by previously published obesity-associated variants (and those in LD with these variants), while that explained by novel and refined variants is in pink. The numbers represent the number of lead SNPs in each of these categories (published / refined and novel).

Table 2: Lead SNPs identified from genome-wide association studies (GWAS) of posterior probability of membership in an adiposity-change cluster (high gain k1, high/moderate gain k1/k2, or high/moderate gain and steady k1/k2/k3), independent of baseline obesity. MAF = minor allele frequency (European-ancestry), TSS = transcription start site, SE = standard error, OR = odds ratio, CI = confidence interval

| Trait | SNP | chr:pos (hg37) | MAF | Nearest TSS | Adiposity-change cluster | Sex-combined OR (95% CI) | Sex-combined P-value | Female OR (95% CI) | Female P-value | Male OR (95% CI) | Male P-value | Sex-heterogeneity P-value |
|--------|---------------|----------------|-------|-------------|--------------------------|--------------------------|----------------------|-----------------------|----------------|--------------------|--------------|---------------------------|
| Weight | rs9467663 | 6:26021456 | 0.418 | H4C1 | k1 | 1.01 (1.01 - 1.01) | 1.6e-09 | 1.01 (1.01 - 1.02) | 4e-06 | 1.01 (1.01 - 1.01) | 0.00081 | 0.785 |
| BMI | chr6:26076446 | 6:26076446 | 0.437 | HFE | k1 | 1.01 (1.01 - 1.02) | 2.1e-09 | 1.01 (1.01 - 1.02) | 7.1e-06 | 1.01 (1.01 - 1.02) | 2.7e-05 | 0.478 |
| BMI | rs11778922 | 8:20493349 | 0.379 | LZTS1 | k1 | 0.99 (0.987 - 0.994) | 2.1e-06 | 0.984 (0.979 - 0.99) | 1.3e-08 | 0.998 (0.992 - 1) | 0.41 | 0.000578 |
| BMI | rs61955499 | 13:112565161 | 0.012 | SOX1 | k1, k2, or k3 | 0.978 (0.961 - 0.995) | 0.012 | 0.935 (0.913 - 0.958) | 3.4e-08 | 1 (0.978 - 1.03) | 0.78 | 4.71e-05 |
| Weight | rs12953815 | 18:2586907 | 0.496 | NDC80 | k1, k2, or k3 | 1 (1 - 1.01) | 0.02 | 1 (0.995 - 1) | 0.97 | 1.01 (1.01 - 1.02) | 1.7e-08 | 2.03e-05 |
| BMI | rs429358 | 19:45411941 | 0.156 | APOE | k1 | 1.02 (1.02 - 1.03) | 4.9e-19 | 1.03 (1.02 - 1.03) | 3e-12 | 1.02 (1.01 - 1.03) | 5.2e-08 | 0.764 |
| BMI | | | | | k1 or k2 | 1.02 (1.02 - 1.03) | 1.1e-17 | 1.02 (1.02 - 1.03) | 2.6e-11 | 1.02 (1.01 - 1.03) | 5.4e-08 | 0.689 |
| BMI | | | | | k1, k2, or k3 | 1.02 (1.02 - 1.03) | 2.5e-16 | 1.02 (1.02 - 1.03) | 9.3e-11 | 1.02 (1.01 - 1.03) | 2.5e-07 | 0.714 |
| Weight | | | | | k1 | 1.02 (1.02 - 1.03) | 1.8e-20 | 1.02 (1.02 - 1.03) | 1.5e-11 | 1.02 (1.01 - 1.03) | 8.9e-08 | 0.807 |
| Weight | | | | | k1 or k2 | 1.02 (1.02 - 1.03) | 2.7e-19 | 1.02 (1.02 - 1.03) | 6.6e-12 | 1.02 (1.01 - 1.02) | 6.8e-07 | 0.886 |
| Weight | | | | | k1, k2, or k3 | 1.02 (1.02 - 1.03) | 1.8e-17 | 1.02 (1.02 - 1.03) | 1e-10 | 1.02 (1.01 - 1.02) | 4.3e-06 | 0.875 |




Figure 3: Association of minor C allele of rs429358, missense variant in *APOE*, with various longitudinal phenotypes. (A) Effect size (beta) and 95% CI for associations of rs429358 with BMI and weight intercepts or linear slope change over time estimated from linear mixed-effects models in all analysis strata. **(B)** Left: OR and 95% CI for association of rs429358 with posterior probability of membership in the BMI and weight high-gain clusters (k1). Right: Modelled trajectories of standardised (std.) covariate-adjusted (adj.) BMI in carriers of the different rs429358 genotypes. **(C)** Proportion of individuals who self-report weight gain, weight loss, or no change in weight over the past year for carriers of each rs429358 genotype. **(D)** Effect size and 95% CI for associations of rs429358 with slopes over time of waist circumference (WC) and waist-to-hip ratio (WHR), adjusted for BMI (-adjBMI), estimated from linear mixed-effects models. **(E)** Effect size and 95% CI for associations of rs429358 with linear slope change in quantitative biomarkers over time, estimated from linear mixed-effects models. Across all panels, estimates of trait change are adjusted for baseline trait values, and P-values for significance are controlled at 5% across number of tests performed via the Bonferroni method. n.s.=non-significant




Figure 4: Genotyped SNP-based heritability of, and genetic correlation between, baseline obesity trait and obesity-change phenotypes. Left column: heritability (h_G^2) estimates and 95% CI, calculated using the LDSC software⁶⁶ on a subset of 1 million HapMap3 SNPs⁶⁷ for the following traits: baseline BMI and weight, estimated from intercepts of linear mixed-effects models of obesity traits over time (u_0), linear slope change in obesity traits over time (u_1 adj. u_0), adjusted for intercepts, and posterior probability of membership in a high-gain BMI or weight cluster, adjusted for baseline trait value ($\text{prob}(k_1)$ adj. u_0). Right column: Genetic correlation, r_G and 95% CI between the two obesity-change phenotypes and corresponding baseline obesity traits. In all panels, circles represent BMI, triangles represent weight; points are coloured by analysis strata (pink: female-specific, green: male-specific, grey: sex-combined). P-values display the level of significance of heterogeneity between the female- and male-specific estimates in each panel.